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Abstract 
Selenium and iodine are essential dietary trace elements required for oxidative 
protection and thyroid hormone metabolism. Iodine deficiency states have been 
linked to serious clinical complications in pregnancy for both mother and child, 
however current assessments of selenium status in the UK pregnant population 
remains limited. The present study aims to assess selenium and iodine 
concentrations during pregnancy in a UK based cohort, investigating for the first time 
potential associations between these two micronutrients. Serum selenium, urinary 
iodine, serum GPx3, serum SEPP1, serum free triiodothyronine (fT3), serum free 
thyroxine (fT4), serum TSH and serum thyroglobulin was measured in 70 prospective 
mothers from the Health & Iodine Status in Babies (HIBA) cohort. Serum samples 
were collected at three time points spanning gestation (~13-15 weeks, ~24 weeks 
and ~36 weeks) and quantified using ICP-MS/ELISA methodologies. Longitudinal 
assessments were performed to monitor how concentrations changed over time. 
Serum selenium concentration was associated with iodine, relevant biomarkers, 
dietary intake and birthweight using repeat measure linear regression. Median 
(interquartile range) serum selenium concentrations across the three time-points of 
pregnancy were 71.4(16.4), 64.2(12.2) and 57.7(15.3) µg/L, respectively. Adjusted 
linear regression analysis found significant associations between selenium and GPx3 
(p<0.001), SEPP1 (p<0.001) and birthweight (p=0.02, first time point), however no 
associations between diet and iodine status were observed. This study found that the 
mothers in this cohort were generally selenium deficient as per recommended 
guidelines (90-100 µg/L). For the first time within a UK population, selenium 
concentration was found to be associated with birthweight during early pregnancy 
with a 10 µg increase in serum selenium concentration leading to a 150 g rise in 
birthweight. As such, the results of this study could have a major impact on the 
nutritional guidance recommended to UK mothers, though further research with a 
larger population is warranted to consolidate findings.  
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A balanced, nutritious diet is crucial for optimal micronutrient intake (National Health 
Service, 2019). Micronutrients play key roles within metabolism and are essential for 
normal biological processes and the aversion of disease (Shenkin, 2006). Specific 
requirements for vitamins, minerals and trace elements for population groups have 
been recommended by independent organisations and government public health 
bodies such as the World Health Organisation (WHO) and the United Kingdom of 
Great Britain and Northern Ireland (UK) Scientific Advisory Committee of Nutrition 
(SACN) (World Health Organisation, 2004; Public Health England, 2016a).  
Additional nutritional requirements are often necessary in certain vulnerable groups 
including expectant mothers (Shenkin, 2006). Pregnancy is a time of substantial 
physiological and metabolic change with increased nutritional demands essential to 
sustaining normal maternal homeostasis and foetal development (Mousa et al., 
2019). Sufficient intake of micronutrients such as iron, vitamin A, folate, selenium and 
iodine are necessary throughout gestation to meet these pregnancy requirements 
(Black, 2007). Micronutrient inadequacy can therefore result in maternal deficient 
states which carries the potential for serious complications in both mother and foetus 
(Mousa et al., 2019). The effects of severe micronutrient deficiencies during gestation 
are well established. For example, extensive research has proven that insufficient 
folate intake both prior to and during pregnancy can result in incomplete neural-tube 
formation during the first 28 days of pregnancy (Medical Research Council Vitamin 
Study Research Group, 1991; Berry et al., 1999). This manifests as debilitating neural 
tube defects including spina bifida and anencephaly (Gernand et al., 2016). To 
prevent these adverse birth outcomes, the UK government recommends folic acid 
supplementation 3 months before conception and throughout the first trimester up to 
12 weeks (National Health Service, 2018).  
In western societies, severe micronutrient deficiencies are less common compared 
to that of the developing world. This is attributed to higher socio-economic status, 
increased access to supplementation and the widespread intake of fortified foods 
(Gernand et al., 2016). However, mild to moderate deficiencies in some 
micronutrients are becoming increasingly more apparent in some western 
demographic areas. This is thought to be the consequence of dietary choices i.e., 
vegetarianism (Allen, 2005), the ease of accessibility to fatty/sugary foods resulting 
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in the reduced consumption of nutritionally rich items (Gernand et al., 2016) and the 
geochemical conditions of particular continents and countries (Johnson et al., 2010).  
Iodine is a micronutrient thought to be mildly deficient within the UK pregnant 
population (Bath et al., 2014; Furmidge-Owen et al., 2014). This is reflected within 
the latest National Diet and Nutrition Survey (NDNS) showing that 17% of women at 
child bearing age were iodine deficient according to the WHO guidelines (Public 
Health England, 2018). Essential to mammalian existence (Zimmermann, 2009a), 
iodine is the key constituent of the two major thyroid hormones; 3,5,3'-triiodothyronine 
(T3) and 3,5,3',5'-tetraiodothyronine/thyroxine (T4) (SACN, 2014). T3 and T4 
influence the majority of cells within the human body via their effects on neuronal 
maturation and basal metabolic rate (Nussey and Whitehead, 2001). Iodine 
insufficiency throughout pregnancy has been linked to adverse birth outcomes such 
as impaired foetal brain development, low intelligence and impaired motor skills 
(Rayman et al., 2009). In conjunction with iodine, selenium is another essential 
micronutrient pivotal for the production of vital selenoproteins including selenoprotein 
P (SEPP1), glutathione peroxidase 3 (GPx3) and iodothyronine deiodinases (DIOs) 
(Wrobel et al., 2016). These selenium containing proteins are implicated in selenium 
transport (Ventura et al., 2017), antioxidative defence (Wu et al., 2015) as well as 
thyroid hormone metabolism (Zimmermann and Kohrle, 2002). Selenium status and 
its effects during pregnancy are poorly recognised compared to other important 
micronutrients such as iodine. Therefore, the aim of this study is to investigate the 
role of both these essential trace elements throughout the course of pregnancy.  
1.1 Selenium  
1.1.1 Background 
Selenium (chemical symbol: Se), was discovered by chemist Jacob Berzelius and 
Johan Gottlieb Gahn in 1817, however it was not linked with human health until 150 
years after its initial discovery. The work of Schwarz and Foltz (1957) first showed 
the importance of dietary selenium, demonstrating that liver necrosis could be 
prevented by feeding rodents yeast with selenium-containing Factor 3. As a relatively 
new discovery in biological terms, the effect of selenium and its incorporation into 
proteins via the essential amino acid selenocysteine (Sec) has started to be linked 
with thyroid function, cardiovascular disease and immune function (Beckett and 
Arthur, 2005; Boyd, 2011). These links with human health have therefore cemented 
selenium as an essential trace element required for mammalian life (Combs, 2001).  
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1.1.2 Selenium Geochemistry  
Selenium resides naturally in the earth’s crust averaging concentrations of ~0.01-2 
mg/kg (Thiry et al., 2012). Existing in both organic (selenomethionine [SeMet]-2 and 
Sec-2) and inorganic forms (selenium selenate+6, selenium selenide-2 and selenium 
selenite+4) (Mehdi et al., 2013), selenium levels in the environment are predominantly 
influenced by soil properties, bioavailability and geographical location (Navarro-
Alarcon and Cabrera-Vique, 2008; Hartikainen, 2005). Selenium soil content is 
determined by a multitude of factors such as rock type, pH, rainfall, soil fertilisation, 
selenium speciation and sulphate concentration (Navarro-Alarcon and Cabrera-
Vique, 2008). Sedimentary rock has higher selenium concentrations compared to 
volcanic rock, limestone and sandstone which are commonly found in mountainous 
areas of Europe i.e. Scotland, Finland and Sweden (Mehdi et al., 2013; Johnson et 
al., 2010). pH also has a substantial effect on the bioavailability of selenium. Alkaline 
conditions tend to favour selenium selenate+6. This makes it more soluble within the 
soil environment, resulting in unimpaired plant uptake. In comparison, acidic 
conditions favour selenium selenite+4. Selenite’s strong adsorption to clay, forming 
chemical oxides reduces the selenium solubility (Combs, 2001; Navarro-Alarcon and 
Cabrera-Vique, 2008). Additionally, rainfall and soil moisture can directly lower plant 
selenium bioavailability via leaching; selenium bioavailability is more profound in drier 
conditions (Combs, 2001). Selenium fertilisers have the ability to drastically alter soil 
selenium concentrations. For example, sodium selenate has been used to increase 
selenium concentration in agricultural produce such as cereal (Hartikainen, 2005). 
Lastly, soil sulphur concentrations can also widely effect selenium uptake in plants. 
Residing in the same elemental family, sulphur and selenium exhibit similar 
properties such as atomic size, oxidation states and ionisation potentials (Mehdi et 
al., 2013). As a result, the antagonistic effect of sulphur can negatively affect 
selenium uptake through plants as they both require use of the same sulphate 
transporters (Terry et al., 2000).  
The combination of these factors means that global selenium distribution ranges 
extensively. Selenium replete soils are found between geographical areas such as 
the Americas, Canada and Japan (Schomburg and Kohrle, 2008), with less replete 
soils commonly found in China, Finland and Denmark (Combs, 2001). Certain parts 
of the UK i.e. Wales has a variable geographical distribution of selenium as a result 
of its diverse geology. For example, rocks and soils in areas such as Snowdonia and 
the Parys Mountain range are typically high in selenium. This is in contrast to the 
lower sandstone areas of mid-Wales where lower selenium concentrations are 
common (Johnson et al., 2010).  
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1.1.3 Dietary Sources of Selenium 
The major source of selenium is derived from the diet, with concentrations being 
dependent on the food type and the quantity consumed (Navarro-Alarcon and 
Cabrera-Vique, 2008). Table 1 shows the average selenium content of foods within 
the UK (SACN, 2013). Cereal grain, fish, and meat produce account for the highest 
intakes of selenium as defined by the latest NDNS Survey Years 7&8 (Public Health 
England, 2018). Brazil nuts contain large concentrations of selenium, however they 
are not consumed frequently within UK populations (Santhosh-Kumar and 
Priyadarsini, 2014). Conversely, fruit and vegetables are relatively low in selenium 
content, providing only small amounts in the human diet (Combs, 2001). Skeletal 
muscle is generally low in selenium concentration, however organ meats such as 
liver and kidney can contain on average up to 4-5 times more selenium (as seen in 
Table 1) (Combs, 2001). Dietary selenium intake varies widely as a consequence of 
geochemical (see section 1.1.2), economic and processing factors. Trade and the 
importation of selenium rich food items from replete countries such as Canadian 
cereal grain, has been shown to raise selenium intake within the UK population 
(MacPherson et al., 1997). Certain cooking processes have also been shown to alter 
selenium content. For example, the boiling of certain foods such as asparagus sees 
selenium concentration drop by as much as 40% (Navarro-Alarcon and Cabrera-












85-690 Salmon* 19.5 
Kidney* 250 Chicken* 16 





Cod* 44 White Bread 6 
Prawns* 30 Cornflakes 5 
Egg* 27 Lamb* 4 
Table 1: Selenium content of UK food sources. The table displays selenium rich 
foods within the UK and the estimated selenium content (µg/100g). *selenium content 
after cooking. Table adopted from SACN (2013).  
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1.1.4 Bioavailability and Metabolism  
1.1.4.1 Selenium Bioavailability 
Four selenium species account for the majority of dietary selenium intake; SeMet, 
Sec, selenium selenite and selenium selenate (Burk and Hill, 2015). Absorption of 
selenium species occurs in the lower intestinal tract through different routes and 
mechanisms, some of which are still yet to be fully characterised (Fairweather-Tait et 
al., 2010). Originating from plant and animal sources, SeMet and Sec (Figure 1) are 
both readily absorbed by the small intestine via the same sodium-dependant 
transcellular absorption pathways like that of their sulphur-containing analogues 
(Roman et al., 2014). This occurs due to selenium and sulphur having similar 
chemical properties (discussed in section 1.1.2) (Navarro-Alarcon and Cabrera-
Vique, 2008). Inorganic selenium selenate is para-cellularly absorbed into the body 
via a passive diffusion process, however the absorption process of selenium selenite 
is still yet to be determined (Roman et al., 2014).  
Overall, the bioavailability of all selenium species is relatively high under normal, 
physiological conditions (~60-90%) (Finley, 2006). However, a number of factors 
have been shown to effect this value including the composition of specific food 
sources (fish and animal meats) and the presence of soil sulphur, certain vitamins 
and heavy metals (Thiry et al., 2012).  
(A) 
  (B) 
Figure 1: SeMet and Sec chemical structures. Chemical formulae of the two main 
organic selenium species; (A) SeMet (B) Sec. Adopted from the Royal Society of 
Chemistry (2015)  
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1.1.4.2 Selenium Metabolic Pathway  
Selenium metabolism a complex process (Navarro-Alarcon and Cabrera-Vique, 
2008). Present knowledge of human selenium metabolism is inferred from rat and 
mouse studies and is depicted in Figure 2 (Rayman, 2008).  
Metabolic pathways are partially dependent on the species of selenium consumed 
(Finley, 2006). Organic SeMet is catabolised to Sec via the trans-selenation pathway. 
Sec generated from this pathway or yielded directly from the diet results in the 
production of hydrogen selenide (H2Se) via catalysis from Sec β-lyase (Rayman, 
2008). SeMet has the added functionality of being non-specifically inserted into 
methionine positions during protein synthesis (Fairweather-Tait et al., 2010), 
occurring via the methionine cycle/trans-sulfuration pathway (Lajin et al., 2016). This 
incorporation can prove to be an important unregulated pool of selenium during 
deficient states (Wrobel et al., 2016). The absorption of inorganic selenium utilises 
the reductive metabolic pathway to produce the same common precursor, H2Se 
(Finley, 2006). Selenium selenate is firstly reduced to selenium selenite by adenosine 
triphosphate (ATP)-sulfurylase (Roman et al., 2014). Further downstream reduction 
of selenium selenite to selenodiglutathione (GS-Se-SG) catalysed by  
dihydronicotinamide-adenine dinucleotide phosphate (NADPH) dependant 
reductases and glutathione reductases leads to H2Se formation (Wrobel et al., 2016). 
As the preferred precursor for selenoprotein production (Fairweather-Tait et al., 
2010), H2Se is used for downstream metabolism of selenophosphate (HSePO32-); the 
selenium donor for selenoprotein synthesis (section 1.1.4.3) (Wrobel et al., 2016). 
Excess concentrations of H2Se are commonly excreted via the urine in the form of 





Figure 2: Metabolic pathway of selenium. Schematic representation of dietary 
selenium metabolism. After selenium is absorbed in the lower intestinal tract, SeMet 
is transported to the liver in the form of selenoalbumin whilst the remaining selenium 
species are transported either intact or through other mechanisms not currently 
established (Roman et al., 2014). This is the primary site of selenium metabolism 
since the majority of selenoproteins are translated and expressed in this organ. The 
reductive pathway (depicted on the right hand side) outlines the metabolic pathway 
that selenium selenate and selenium selenite utilises to produce H2Se (described in 
main text). Organic selenium metabolism is depicted on the left hand side of the 
diagram. SeMet either becomes incorporated non-specifically into proteins via the 
trans-sulfuration pathway or is catabolised to Sec through the trans-selenation 
pathway. Both organic and inorganic metabolic pathways result in the same common 
precursor, H2Se. Selenium regulation and excretion is also controlled by the liver. 
The organ has the ability to regulate whole body selenium by secreting transport 
selenoproteins into the plasma for use by other tissues (Burk and Hill, 2015). In 
periods of saturation, excess selenium is excreted through the metabolic pathways 
shown above. These processes involve the methylation to either a selenosugar from 
H2Se or via further downstream methylation to dimethylselenide where selenium is 
exhaled in the breath (Rayman, 2008). Figure adapted from Wrobel et al. (2016), 




1.1.4.3 Selenoprotein Synthesis 
Selenoprotein synthesis is complex process involving specialised reactions leading 
to the production and insertion of a Sec amino acid (Figure 3) (Wrobel et al., 2016). 
Five main molecular components are utilised: selenoprotein messenger ribonucleic 
acid (mRNA), selenocysteyl—transfer ribonucleic acid (tRNA)[ser]sec, a specialised 
translational elongation factor (EFSec), a stem and loop structure called the 
selenocysteine insertion sequence (SECIS) and the SECIS binding protein 2 (SBP2) 
(Drutel et al., 2013; Labunskyy et al., 2014)  
Sec is the only known amino acid whereby biosynthesis occurs on its own, 
specialised tRNA (selenocysteyl-tRNA[ser]sec). As one of the largest eukaryotic tRNA 
molecules at 90 nucleotides in length (Schomburg and Schweizer, 2009), it is formed 
from precursors derived from the selenium metabolic pathway (Figure 2). Firstly, 
tRNA[ser]Sec  undergoes aminoacylation with serine which is then phosphorylated to 
produce O-phosphoseryl-tRNA[ser]sec (Roman et al., 2014). The active selenium 
precursor, HSePO32 (catalysed by Sec synthase) (Labunskyy et al., 2014) then 
replaces the phosphoryl moiety of the tRNA to produce selenocysteyl-tRNA[ser]sec 
(Brigelius-Flohe and Maiorino, 2013). Sec incorporation is coded by the ‘UGA’ codon 
in the open reading frame within the selenoprotein mRNA. Since the stop codon 
‘UGA’ normally signals translation termination, the stem-loop structure at the 3’ 
untranslated region of the selenoprotein mRNA (SECIS) dictates the correct 
translation of the ‘UGA’ to Sec by the selenocysteyl-tRNA[ser]sec (Wrobel et al., 2016). 
SECIS also recruits two trans-acting factors which are required for efficient 
recognition of the ‘UGA’ codon; SBP2 and EFSec (Drutel et al., 2013; Labunskyy et 
al., 2014). The interactions of both of these elements recruit selenocysteyl-tRNA[ser]sec 







Figure 3: Eukaryotic Sec insertion. Machinery involved in the incorporation of a Sec molecule into a forming selenoprotein. Normal ribosomal 
translation of a ‘UGA’ codon would result in polypeptide termination, however the presence of the SECIS at the 3’ untranslated region of the mRNA 
dictates that the ‘UGA’ codon should be recoded as a Sec molecule (Wrobel et al., 2016). In response, the specialised selenocysteyl -tRNA[ser]sec 
translates ‘UGA’ as Sec. Two main trans-acting factors; SBP2 and EFSec are essential to this process. SBP2 contains a specific RNA binding 
domain that binds SECIS elements with a high affinity. In addition, SBP2 also recruits EFSec which signals selenocysteyl-tRNA[ser]sec to the site of 
translation, therefore allowing Sec to be incorporated into the forming selenoprotein. Eukaryotic initiation factor 4a3 (eIF4a3), ribosomal protein L30 
and nucleolin also serve as further SECIS-binding proteins. Whilst L30 aids Sec insertion, eIF4a3 and nucleolin act as regulatory proteins, modulating 
selenoprotein synthesis (Labunskyy et al., 2014). Adopted from Labunskyy et al. (2014).  
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1.1.5 Selenoproteins  
Selenium exerts its biochemical function at the active site of selenoproteins via the 
Sec residue (Thiry et al., 2012; Duntas and Benvenga, 2015). Known as the “21st 
amino acid”, Sec is an extremely effective biological redox catalyst implicated in 
important enzymatic functions such as thyroid hormone metabolism, fertility, redox 
reactions and lipid peroxidation (Brown and Arthur, 2007; Rayman, 2000; Ashton et 
al., 2009). Glutathione peroxidase 1 (GPx1) was the first selenoprotein to be 
discovered in 1973. Subsequently, a further 29 human selenoproteins encoded by 
25 human genes make up the current human selenoproteome (Labunskyy et al., 
2014). The main selenoproteins families implicated in thyroid homeostasis (Ventura 
et al., 2017) are described in Table 2.  
Selenoprotein Family Localisation Key Functions 
Glutathione 
Peroxidase  
1, 2, 3, 4 and 6 


















1, 2 and 3 




thioredoxin for DNA 
synthesis. 
TrxR2: 




Deiodinase 1, 2 and 3 
(DIO1, DIO2, DIO3) 
DIO1: Thyroid, liver, kidney 
Activation/deactivation 




DIO3: Placenta, brain 
Table 2: Key selenoprotein families involved in thyroid hormone metabolism. 
Localisation and general function of the four selenoprotein families required for 
thyroid homeostasis. Adapted from Rayman (2000), Rayman (2012), Ventura et al. 
(2017) and Moghadaszadeh and Beggs (2006).  
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1.1.5.1 Glutathione Peroxidase 
Glutathione peroxidases (GPx) are a large family of antioxidant enzymes. There are 
five main human selenocysteine containing GPx’s: GPx1, GPx2, GPx3, GPx4 and 
GPx6, all of which are involved in the reduction of hydrogen peroxide (H2O2) using 
glutathione (GSH) as the reductant cofactor (Brigelius-Flohe and Maiorino, 2013). 
This is achieved via a three-step pathway as seen in Figure 4.  
GPx3 is a glycosylated tetrameric enzyme with a molecular weight of 93 kilo Dalton 
(KDa). It is the only extracellular GPx, being distributed within the plasma (Roman et 
al., 2014). It was first found in the proximal convoluted tubules of the kidneys where 
it is basolaterally secreted into plasma, however it has since been found in other 
tissues such as the thyroid gland (Brigelius-Flohe and Maiorino, 2013). Here it is 
secreted at the apical side of the thyrocyte membrane and is involved with the 
process of converting excess H2O2 after the iodination of tyrosyl residues into water 
(H2O) (Rayman, 2018). GPx3 is sensitive to the concentration of whole body 
selenium with deficiency potentially leading to an impairment of antioxidant activity 
within the thyroid (Schomburg, 2011). As 90% of all GPx produced is that of GPx3, it 
makes it a good biomarker of overall selenium status (Burk and Hill, 2015). 
 
Figure 4: GPx oxidative pathway. A schematic diagram showing the GPx 
oxidation/reduction pathways. This has been proven for GPx1, GPx3 and GPx4. The 
selenol residue (GPx-Se-) is oxidised by a hydroperoxide (ROOH) to form selenic 
acid (GPx-SeOH) (Roman et al., 2014). To regenerate the enzyme back to its selenol 
form, two molecules of GSH are reduced. The first GSH forms a selenadisulfide 
(GPx-Se-SG), with the second GSH reducing GPx-Se-SG to form a glutathione 
disulfide (GSSG) by-product and a regenerated selenol residue (Brigelius-Flohe and 
Maiorino, 2013). Figure adopted from Brigelius-Flohe and Maiorino (2013) 
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1.1.5.2 Selenoprotein P  
SEPP1 consists of two main domains: the N- and C- terminals. In humans, the larger 
N-terminal domain contains one highly conserved Sec residue whereas the C-
terminal domain contains the remaining nine. With a total of 10 Sec residues, SEPP1 
is the highest selenium containing glycoprotein in the entire human body (Burk and 
Hill, 2009).  
SEPP1 is synthesised in most tissues as seen by the presence of SEPP1 mRNA, 
however it is rapidly produced and exported in large quantities from the liver. 
SEPP1’s main function is to act as a selenium transporter to extra-hepatic tissues 
such as the brain, testis and kidneys (Burk and Hill, 2005). For example, SEPP1 is 
bound by a lipoprotein receptor in the testis, facilitating the uptake of selenium into 
spermatozoa (Burk and Hill, 2009). In mouse models, selenium concentrations in the 
brain are diminished in the presence of SEPP1 gene deletion, showing that SEPP1 
is crucial for selenium transportation (Hill et al., 2003). Studies have also suggested 
that SEPP1 exhibits some antioxidative properties (Shetty and Copeland, 2018). The 
‘UxxC’ portion of the protein (see Figure 5) contains several conserved sequences 
similar to thioredoxin-fold proteins. This discovery suggests that the N-terminal 
domain shows thiol-redox function, owing to potential antioxidative properties (Burk 
and Hill, 2009). SEPP1 is the preferred biomarker of choice when assessing selenium 
status as over 50% of all plasma selenium is contained in SEPP1. This makes SEPP1 
concentration a good biomarker selenium status within a population (Mostert, 2000).  
 
 
Figure 5: N and C terminal domains for SEPP1.SEPP1’s ten Sec residues are 
depicted by the red ‘U’ codon. Within the N-terminal domain, one Sec molecule is 
present with a thioredoxin-like motif (UxxC), two histidine rich motifs (H-rich) are 
accountable for the heparin binding properties of the protein, the heparin binding site 
(HBS) allows heparin binding in a pH sensitive manner and there are three 
carbohydrates within the N-domain (N-CHO). The remaining 9 Sec molecules are 
contained within the final third of the protein (C-terminal). (A) N-terminal (B) C-
terminal. Figure adopted from (Burk and Hill, 2009).   
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1.1.5.3 Iodothyronine Deiodinases  
The family of three Sec containing DIO (iodothyronine deiodinase 1 (DIO1), 
iodothyronine deiodinase 2 (DIO2) and iodothyronine deiodinase (DIO3)) are vital 
selenoproteins implicated in correct thyroid hormone function (Larsen and Zavacki, 
2013). All three act as oxidoreductases, with an active site containing one Sec 
residue that is responsible for catalysing the activation or deactivation of 3,5-diiodo-
L-thyronine (T2), T3, 3,3’,5’-triiodothyronine (reverse triiodothyronine, rT3) and T4 
(Roman et al., 2014). All three membrane proteins are similar in structure, differing 
in their cellular localisations. DIO1 and DIO3 are located within plasma membranes, 
whereas DIO2 is located within the endoplasmic reticulum (Larsen and Zavacki, 
2013).  
The DIO’s are instrumental in maintaining and controlling thyroid hormone 
homeostasis (Labunskyy et al., 2014). DIO1 and DIO2 catalyse outer ring 
deiodination of T4 to produce active T3 (Labunskyy et al., 2014). DIO1 is responsible 
for 80% of the total circulating T3 and is found primarily in the liver, thyroid and kidney 
whilst DIO2 is found to be highly active in the central nervous system, anterior 
pituitary and brown adipose tissue (Chan et al., 2003). In comparison, DIO3 (and 
under certain conditions, DIO1) are responsible for the deactivation of T4 and T3 into 
rT3 and T2 by catalysing the deiodination of the inner ring (Figure 6). During 
pregnancy, DIO3 prevents against excessive fluctuations in foetal thyroid hormone 
supply and is present in abundance in the placenta and uterus (Larsen and Zavacki, 
2013).  
 
Figure 6: DIO regulation. The diagram depicts the metabolism of the thyroid 




1.1.6 Selenoprotein Hierarchy  
The adverse consequences of selenium deficiency result in the premature 
termination of proteins at the ‘UGA’ codon and the increased degradation of 
selenoprotein mRNA; both leading to decreased selenoprotein expression (Wingler 
et al., 1999). Therefore, in order to manage protein expression in selenium deficient 
states, selenoproteins are ranked in a selected hierarchy dependant on their 
biological importance (Wingler et al., 1999; Burk and Hill, 2015). The hierarchical 
principles controlling selenoprotein expression aim to distribute selenium supply to 
the most vital selenoproteins during periods of deficiency. Subsequently, this allows 
vital functions such as metabolism and growth to continue unimpaired (Schomburg, 
2011). Two main principles are witnessed in higher mammals: 1) the biosynthesis of 
preferential selenoproteins and 2) unequal tissue distribution of selenium 
(Schomburg and Schweizer, 2009). The expression of selenoproteins are directly 
affected by selenium bioavailability. Selenoproteins such as GPx1, GPx3 and 
selenoprotein W are ranked low in the selenoprotein hierarchy resulting in 
downregulation in periods of selenium deficiency. This is in contrast to proteins such 
as TrxR1, TrxR3, SEPP1 and DIO who rank highly and are less dependent on dietary 
selenium intake (Labunskyy et al., 2014; Brigelius-Flohe and Maiorino, 2013; 
Solovyev et al., 2018). A number of studies in rodents have explored this principle. 
Bermano et al. (1995) investigated the hierarchical system of three selenoproteins; 
DIO1, GPx1 and GPx4. Results indicated that the dietary intake of selenium 
regulated the activity of selenoprotein expression and the corresponding mRNA 
concentrations. GPx1 concentrations fell rapidly in a selenium deficient state, 
whereas GPx4 and DIO1 concentrations were continually maintained. Hill et al. 
(1992) also found similar results. Under selenium deficient conditions, decreases in 
liver SEPP1 and GPx1 concentrations were measured, however GPx1 fell rapidly 
before any decreases in SEPP1 were witnessed. A pre-translational effect was also 
noticed in the selenoprotein mRNA. DIO1 and SEPP1 mRNA was found to be more 
resistant to selenium deficiency compared to GPx1. It was hypothesised that the 
limited selenocysteyl-tRNA[Ser]Sec machinery was being directed towards the 




Specific organs also have the increased capacity to retain selenium as per its 
individual requirements. The brain, thyroid and reproductive organs store selenium 
more efficiently compared to the liver, kidney and muscle (Berry, 2005). This was 
shown in a study conducted by Behne et al. (1988) who found that selenium 
distribution in rats were directed to certain tissues in periods of selenium insufficiency. 
Retention of selenium was found to be 20-50 times higher in organs such as the 
brain, ovaries and endocrine glands compared to the kidneys, liver and heart.  
1.1.7 Selenium Requirements 
Selenoproteins are dependent on sufficient selenium intake in order to guarantee 
optimal protein expression and avoid impaired functionality (Mostert, 2000). Due to 
the large geographical variation in selenium concentration (as described in section 
1.1.2), there are no internationally recognised reference ranges for serum selenium 
concentrations (Thomson et al., 2007b). Therefore, dietary values of selenium intake 
are based on maintaining a serum selenium concentration that will sustain and 
maximise optimal GPx output (Ashton et al., 2009). This threshold varies between 
studies, however levels are commonly expressed as being between 90-100 µg/L 
(Stoffaneller and Morse, 2015; Combs, 2001; Thomson et al., 1977). Recommended 
dietary selenium intake also varies by country. Within the UK and Belgium, Dietary 
Reference Values (DRV) for selenium intake is 60 µg/day for adult women, increasing 
to 75 µg/day for adult men and lactating women. The UK does not suggest increasing 
selenium intake during pregnancy (Public Health England, 2016b), however Belgium 
recommend an increase of 5 µg/day (Mehdi et al., 2013). This is in contrast with the 
United States of America (USA) and the WHO recommendations where 
Recommended Dietary Allowances (RDA) measure 55 µg/day for both sexes in the 
USA (Institute of Medicine Food and Nutrition Board (US), 2000) and 40 µg/day for 
males and 30 µg/day for females as per the WHO guidelines (Ventura et al., 2017). 
The changes in RDAs/DRVs between countries can be attributed to the varying 





Some countries have taken the step to supplement selenium into mineral fertilisers 
to increase selenium intake. For example, since the 1980’s, Finland have fortified 
crops and animal feed with sodium selenate due to a lack of bioavailable selenium in 
its soils. As a result, selenium intake and serum concentrations within the population 
has risen significantly over the past 40 years. Dietary intake has increased from 0.025 
mg/day to 0.8 mg/day; this intake currently meets requirements as set by the 
European Union (EU) and USA regulatory bodies. Average serum selenium 
concentrations have also risen significantly in this time. Before selenium 
supplementation, the mean concentration was 0.89 µmol/L; in the 2010’s the 
measurement stood at 1.4 µmol/L, making it above serum selenium levels seen in 
most of Europe (Alfthan et al., 2015).  
There is a fine line between too little and too much selenium in the diet. Chronic 
toxicity can lead to selenosis. Manifestations of this are signalled by brittle/loss of 
hair, gastrointestinal problems and foul breath. To prevent excessive intake, many 
countries such as the USA and the WHO have set upper limits of 400 µg/day and 
300 µg/d respectively (Mistry et al., 2012).  
1.1.8 Selenium and Health  
Two main disease states as a result of low selenium intake are ‘Keshan’ disease and 
‘Kaschin-Beck’ disease. Prevalence of these diseases are common in mountainous 
areas of rural China and Siberia (Navarro-Alarcon and Cabrera-Vique, 2008). 
Keshan disease was first discovered in the ‘Keshan’ area of China, displaying as an 
endemic juvenile cardiomyopathy occurring in 2-10 year olds and in some instances, 
women of child bearing age (Combs, 2001). Kaschin-Beck disease, also referred to 
as “big-joint disease” (Hartikainen, 2005), is a rheumatoid condition commonly seen 
in 5-13 year olds. It is caused by oxidative damage to cartilage resulting in deformed 
bone structure i.e. shortened fingers and toes, enlarged joints and in very extreme 
cases, dwarfism (Navarro-Alarcon and Cabrera-Vique, 2008). Disease states were 
distributed along a belt of land running from the northeast to the southwest of the 
country known to contain soils with very low selenium bioavailability (Hartikainen, 
2005).  
Adverse cardiovascular events in individuals have been linked with low selenium 
status. A study conducted in Finland before mandatory selenium fertilisation 
assessed the incidence of coronary heart disease (CHD), myocardial infarction (MI) 
and their associations with selenium status. Results found that serum selenium below 
45 µg/L statistically increased the risk of both CHD and MI (Salonen et al., 1982). 
Oxidative stress has been shown to damage vascular endothelial cells, resulting in 
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the exacerbation of cardiovascular disease (CVD). Since certain selenoproteins are 
renowned for their oxidative defence mechanisms, it has been hypothesised that 
adequate selenium intake could prevent the onset of CVD and defend against 
reactive oxidative species (ROS) (Roman et al., 2014). Low levels of selenium have 
also been linked with male infertility. GPx4 and SEPP1 are two selenoproteins 
involved in spermatogenesis. GPx4 found in the mitochondrial capsule is responsible 
for two key processes (Mistry et al., 2012). During early phase spermatogenesis, 
GPx4 antioxidative properties prevent against oxidative stress. For normal 
spermatozoa formation during later phase spermatogenesis, GPx4 is crucial for 
creating crosslinks with proteins, becoming a structural component within the 
flagellum which aids sperm motility. A study in Japan showed that a proportion of 
infertile men had GPx4-defective sperm (Rayman, 2012). SEPP1 is also required in 
the testis to facilitate selenium transport, as shown in SEPP1 knockout mice. SEPP1 
transport to the apolipoprotein E receptor-2 was insufficient, leading to impaired 
spermatogenesis and defective spermatozoa, resulting in infertility (Burk and Hill, 
2009). Sufficient dietary selenium has been shown to stimulate and enhance immune 
response by improving the proliferation of activated T-lymphocytes, increasing 
natural killer cell activity and increasing cytotoxic lymphocyte-mediated tumour cyto-
toxicity (Ventura et al., 2017; Rayman, 2012). In contrast, adverse 
immunocompetence such as low T-lymphocyte counts and lymphocyte proliferation 
have both been associated with low selenium concentration (Rayman, 2000; Brown 
and Arthur, 2007).  
Proving a conclusive link between selenium concentration and cancer still remains 
challenging (Roman et al., 2014). A landmark trial performed by Clark et al. (1996) 
was one of the first to link selenium concentration and incidences of carcinoma. 
Whilst there was no association between selenium and the primary outcome of the 
study, cancer mortality and the frequency of site specific cancers such as prostate, 
lung and colorectal was significantly lower for participants receiving 200 µg selenium 
supplementation, compared to those in the placebo group. However, reanalysis of 
this study data by Reid et al. (2002) concluded that lung cancer incidence was not 
significantly associated with selenium supplementation. Further research is required 




1.1.8.1 Selenium Deficiency and Pregnancy  
During pregnancy, adequate placental transfer of selenium is required for foetal 
selenoprotein production and thyroid hormone metabolism to enable normal growth 
and development (Zimmermann and Kohrle, 2002). Impaired transfer due to 
selenium insufficiency has been linked to adverse birth outcomes (Burk et al., 2013), 
however, few studies so far have investigated these effects. Studies that have 
investigated this potential link found low levels of selenium and selenoproteins during 
pregnancy were associated with conditions such as pre-eclampsia, pre-term birth 
and low birth weight.  
A Bangladeshi study conducted by Haque et al. (2016) investigated the effects of 
selenium concentration and pre-eclampsia. In 192 pregnant women, mean selenium 
concentration was shown to be significantly lower in the pre-eclamptic group 
compared to control groups (23.76 µg/L and 32.18 µg/L respectively, p<0.05). Mistry 
et al. (2008) found similar results in a cohort of UK pregnant women. Mean selenium 
concentration in women who had pre-eclamptic pregnancies was significantly lower 
in comparison to mothers who did not (39.7 µg/L and 58.4 µg/L respectively, 
p<0.001). A further study performed by Rayman et al. (2003) found that toenail 
selenium levels in moderately/severe pre-eclamptic pregnant women were 
significantly lower than pregnant women without the condition. In addition, when 
selenium concentration was ranked into thirds, it was found that half the pre-
eclamptic women were classified in the lowest third. A Dutch study performed by 
Rayman et al. (2011) investigated selenium status and the association with pre-term 
birth. Logistic regression showed that women with a selenium concentration in the 
lowest quartile had twice the risk of pre-term birth (odds ratio: 2.0, 95% confidence 
interval (CI): 1.19-3.47). Low selenium during pregnancy has also been associated 
with low birthweight. A study conducted in the USA by Bogden et al. (2006) found 
that mothers with a serum selenium concentration in the lowest ten percent during 
early pregnancy (median 8.7µg/L) were significantly associated with low birth weight. 
These studies highlight the potential importance of adequate selenium concentration 





1.2.1 Iodine Geochemistry  
Iodine concentrations are known to be unevenly distributed within the environment 
(Zimmermann et al., 2008). Levels are heavily dependent on a number of factors 
including geographical location, rock type, iodine fixation potential of the soil, climate, 
topography and the proximity to the sea (Johnson, 2003). Soil geochemistry provides 
the link between the environmental iodine and the food chain. As iodine 
concentrations are reliant solely upon dietary intake, the specific geochemistry of an 
area is incredibly important for iodine adequacy (Johnson, 2003). Mountainous areas 
such as the Himalayas and the French Alps are susceptible to a lack of iodine due to 
igneous rock having a lower iodine content in comparison to sedimentary rock 
(Johnson, 2003). The ‘goitre belt’ prevalent in the UK during the early to mid-1900’s 
(Figure 7) lay on carboniferous limestone rock which was thought to cause insufficient 
iodine levels in large swathes of the country (Saikat et al., 2005). Incidences of goitre 
(enlarged thyroid) were reported from Cornwall, through the Midlands and up into 
areas of Derbyshire and was commonly referred to as the ‘Derbyshire Neck’ (Bath 
and Rayman, 2015). 
 
Figure 7: UK goitre belt. The shaded area of the UK indicates the widespread 




1.2.2 Dietary Sources of Iodine 
In the UK, seafood, fish, eggs and dairy account for the majority of iodine intake as 
shown in Table 3 (SACN, 2014). Dairy consumption is the main source of dietary 
iodine across all UK population groups (Public Health England, 2018) with 34% of all 
iodine intake for adults (aged 19-64) coming from dairy based produce. In the farming 
industry, fortified livestock feed and iodine containing cleaning products have been 
shown to increase iodine levels in meat and dairy produce (Zimmermann, 2009a). In 
the 1930’s, the UK saw a steady rise in milk iodine levels as farmers implemented 
iodised cattle feed along with iodised salt licks as they were thought to have major 
reproductive benefits for the livestock. This coincided with an increase in milk 
consumption, which in turn saw iodine levels rise within the UK population (Phillips, 
1997). Conversely, a number of edible plants and vegetables are thought to inhibit 
the iodine uptake process due to competition from glucosinolates. For example, 
broccoli, kale, turnips and cabbage (Zimmermann, 2009a). The first report of this was 
in 1928 when cabbage feeding in rats resulting in goitre development (Chesney et 
al., 1928). Soy bean has also been identified as a goitrogen due to its role in the 
impairment of thyroid peroxidase activity (Eastman and Zimmermann, 2018).  
 
Food Iodine content (µg/100g) 
Mussels, cooked 247 
Cod, baked 161 
Egg yolk, boiled 137 
Eggs, whole, boiled 52 
Milk chocolate 51 
Sea salt 50 
Whole milk, pasteurised, average 31 
Semi-skimmed milk, pasteurised, 
average 
30 
Skimmed milk, pasteurised, 
average 
30 
Cheddar cheese 30 
Table 3: Iodine rich food sources in the UK. The table displays iodine rich foods 




1.2.3 The Thyroid Gland 
The thyroid is a butterfly-shaped endocrine gland responsible for the production of 
the two key iodine containing hormones; T3 and T4. It is located in the lower part of 
the neck, spanning either side of the trachea consisting of a right and left lobe – both 
are connected by tissue called the isthmus (Figure 8) (Martin;, 2015). Each lobe 
measures approximately 2 cm in thickness, 4 cm in length and has a combined 
weight of around 15-25 g, making it one of the largest endocrine glands in the body 
(based on a normal, disease free state) (Mohebati and Shaha, 2012). At a 
microscopic level, the epithelial cells (thyrocytes) are arranged into a follicle around 
a protein rich matrix called the colloid (see top left Figure 9). The follicular cells are 
orientated to facilitate the transportation of iodine into the cell from the capillaries 
through the basolateral membrane (Nussey and Whitehead, 2001), along with the 
transfer of precursors in and out of the follicular lumen at the apical surface (Di Jeso 
and Arvan, 2015).  
 
 
Figure 8: The thyroid gland. The diagram shows the key parts of the thyroid gland 




1.2.4 Iodine Metabolism 
Iodine metabolism is depicted in Figure 9. The first stage of iodine metabolism is 
known as iodine trapping. After ingestion, iodine is converted to iodide, absorbed 
through the small intestine and transported through the plasma to the thyroid gland 
(World Health Organisation, 2004). Iodide is then taken up into the thyrocytes by the 
sodium/iodide symporter found at the basolateral membrane of the follicular cell. One 
iodide ion and two sodium ions are transported into the cell against both chemical 
and electrical gradients with sodium returning to the capillary via the 
sodium/potassium ATPase. Simultaneously, thyroglobulin is produced at the rough 
endoplasmic reticulum in the thyrocytes, where individual tyrosine molecules 
combine to form a complete peptide (140 tyrosine molecules per thyroglobulin 
molecule). Fully assembled, the vesicle containing thyroglobulin moves via the Golgi 
apparatus to the apical membrane where it enters into the follicular colloid via 
exocytosis. Newly imported iodide molecules move through the follicular cell to the 
apical membrane where they are transported via the pendrin transporter into the 
colloid space. Iodide is then oxidised, with two iodide ions required to produce one 
diatomic iodine molecule. This oxidation is catalysed by both thyroid peroxidase 
(TPO) and H2O2. The resulting iodine molecule covalently links with the tyrosyl 
residues of thyroglobulin to produce either monoiodotyrosine (MIT) or diiodotyrosine 
(DIT) precursors. Iodination is followed by a coupling reaction of the tyrosyl molecules 
where either T3 or T4 is produced (two DIT molecules couple to form T4, one MIT 
and one DIT molecule couple to form T3). Under the influence of thyroid stimulating 
hormone (TSH), iodinated thyroglobulin then moves back into the cell via endocytosis 
(Nussey and Whitehead, 2001). Once in the cell, lysosomes fuse with the colloid 
droplets, cleaving T3, T4, MIT and DIT from the thyroglobulin molecule in the 
cytoplasm. Around 10% of the newly formed T4 is mono-deionised to T3 before both 
hormones move towards the basolateral membrane. Remaining MIT and DIT 
molecules are completely deiodinated and recycled by tyrosine dehalogenase. The 
new thyroid hormones are secreted into the bloodstream where they circulate in 
either bound or unbound forms (Nussey and Whitehead, 2001; Ahad and Ganie, 
2010; Di Jeso and Arvan, 2015; Rousset et al., 2015).  







Figure 9: Iodine metabolism within the thyrocytes. Depiction of iodine transportation and synthesis within the thyroid follicular cell to produce 




1.2.5 Key Thyroid Hormones 
1.2.5.1 Thyroxine and Triiodothyronine 
As described in section 1.2.4, T3 and T4 are metabolised in the follicular cells of the 
thyroid gland and excreted into the blood stream. Approximately 100 µg of thyroid 
hormones are released from the thyroid daily (Nussey and Whitehead, 2001), with 
the T4 prohormone excreted at nearly 10-fold the concentration of active T3 (Larsen 
and Zavacki, 2013). The majority of T4 and T3 is then transported through the 
circulatory system bound to carrier proteins, such as thyroxine binding globulin (TBG) 
and albumin. Only 0.03% of T4 and 0.3% T3 travel unbound as free 3,5,3',5'-
tetraiodothyronine (fT4) and free 3,5,3'-triiodothyronine (fT3) (Refetoff S., 2015). The 
bound fraction acts as a ‘circulating reservoir’ with only the unbound fraction of the 
thyroid hormones acting upon target cells (Nussey and Whitehead, 2001).  
T4 is converted by selenium containing DIOs into either active fT3 or non-active rT3. 
fT3 binds to high affinity T3 nuclear receptors in the nucleus of the cell (World Health 
Organisation, 2004). This helps to regulate downstream gene expression which in 
turn effects a plethora of bodily processes such as somatic growth and central 
nervous system development in children, along with regulation of the metabolic rate 
and the synthesis of key enzymes in adults (Velasco et al., 2018).  
T3 
T4 
Figure 10: T3 and T4 chemical structures. The iodine positions for T3 and T4 are 
depicted by Figure 10. 64% of the molecular weight of T4 is composed of iodine 




1.2.5.2 Thyroid Stimulating Hormone 
TSH is produced by the anterior pituitary gland at the base of the brain. It is a large 
glycoprotein weighing 28 KDa and consisting of two subunits – α and β. TSH is 
responsible for regulating thyroid hormone homeostasis via a negative feedback 
mechanism controlled by the hypothalamic-pituitary (HPT) axis (Nussey and 
Whitehead, 2001). As the brain specific DIO2 rapidly converts T4 into T3, low levels 
of T4 are recognised and thyrotropin releasing hormone (TRH) is released from the 
hypothalamus into the circulatory system (Larsen and Zavacki, 2013). TRH 
stimulates thyrotrophs in the anterior pituitary to upregulate TSH production which 
allows an increased concentration of iodine into the cell via the sodium/iodide 
symporter. This results in increased hormone synthesis and the release of T4 and T3 
(Pirahanchi and Jialal, 2018). In contrast, when T4 and T3 levels are excessive, TSH 
production ceases and the hypothalamus secretes somatostatin, inhibiting TSH 
release and in turn, reducing intestinal iodine uptake and renal retention (SACN, 
2014).  
 
Figure 11: The HPT axis. A depiction of the negative feedback mechanism 
controlled by the HPT axis. Low T3 and T4 concentrations stimulate TRH release, 
resulting in the upregulation of TSH in the pituitary gland. This stimulates the 
thyrocytes to increase thyroid hormone production. Figure adopted from Ortiga-





Thyroglobulin is one of the largest molecules within the human proteome. Located 
on chromosome 8, the dimeric 660 KDa protein is exclusively synthesised in the 
thyroid gland making it the most specific and abundant intrathyroidal protein in the 
human body (Zimmermann and Andersson, 2012). Stored within the colloid, its 
concentrations range from ~200-300 g/L (Rousset et al., 2015), where it facilitates 
the production of both T3 and T4 by the covalent linkage of iodide to tyrosyl residues 
to produce MIT and DIT (described in section 1.2.4). About 40% of T4 is synthesised 
at the extreme N-terminus of the thyroglobulin protein (tyrosyl 5), compared to 
roughly 20% at tyrosyl site 2554. T3 is predominantly formed at the C-terminal 
(Rousset et al., 2015) On average, only a fraction of the tyrosine molecules are 
actually iodinated (10-20 tyrosyl molecules per thyroglobulin molecule out of a 
possible 140) (Di Jeso and Arvan, 2015).  
As thyroglobulin is thyroid specific, it is a good marker of thyroid status. Thyroglobulin 
containing endosomes can cause transcytosis where small amounts are released 
into the circulation (Zimmermann et al., 2013). During iodine deficiency, an increase 
in TSH causes the follicular cells of the thyroid to enlarge causing increased amounts 
of thyroglobulin to be released into the blood stream. For example, in a normal, iodine 
sufficient individual, thyroglobulin concentrations can range from 5-14 µg/L compared 
to that of an individual with goitre displaying mean concentrations of 94-208 µg/L (Ma 





1.2.6 Iodine Requirements 
Iodine requirements are dependent upon population demographic. Regulatory bodies 
such as the WHO and the United States Institute of Medicine (IoM) differ on their 
recommendations as seen in Table 4 (World Health Organisation, 2007; 
Zimmermann et al., 2008). UK specific iodine requirement values were set by the 
Committee on Medical Aspects of Food and Nutrition Policy (COMA) in 1991. To this 
day, Reference Nutrient Intakes (RNI) remain unchanged. Both adult men and 
women are required to have an iodine intake of 140 µg/day, 10 µg less than 
















































Pregnancy 250 Pregnancy 220 Pregnancy N/A 
Lactating 
Women 
250 Lactation 290 Lactation N/A 
Table 4: Recommendations for dietary intake of iodine. Daily iodine requirements 
(µg/day) in different population groups according to the WHO, IoM and COMA. 
Adapted from Zimmermann (2009a) and COMA (1991). RDA: Recommended 





1.2.6.1 Iodine Requirements during Pregnancy 
Pregnancy is associated with major changes in thyroid function and iodine 
requirements (Glinoer, 2007). This is the result of three main factors: maintaining 
normal maternal thyroid gland function (euthyroidism) whilst also transferring T4 to 
the foetus in early gestation for growth and development; transferring iodine across 
the placenta for foetal thyroid hormone production in later gestation and to 
compensate for the increase in renal iodine clearance (Zhang et al., 2017). 
In early pregnancy, an increase in TBG stimulated by a rise in oestrogen and 
enhanced hepatic synthesis starts to effect hormone homeostasis (Elnagar et al., 
1998; Lazarus, 2011). Simultaneously, increased renal blood flow and glomerular 
filtration rate during early gestation leads to an increase in renal iodine clearance by 
as much as 50%. As a result, the circulating plasma iodine pool decreases 
significantly (Glinoer, 2007). Towards the end of the first trimester, the concentrations 
of human chorionic gonadotrophin (hCG) has a weak, stimulatory effect on thyroid 
hormone production (Glinoer, 2004), resulting in lower TSH values and higher 
concentrations of free thyroid hormones (Fantz et al., 1999). Daily maternal T4 
increases of approximately 50% require an additional ~75-150 µg of T4 to maintain 
both placental iodine transfer and maternal euthyroidism. This translates to an extra 
50-100 µg of dietary iodine intake per day (Delange, 2007). As the foetal thyroid gland 
does not function until roughly 12 weeks gestation, it is imperative that the mother 
has sufficient iodine to keep up with the demands throughout pregnancy to sustain 
euthyroidism and ensure normal brain development in utero for the foetus. (Glinoer, 
2007). The foetal thyroid starts to concentrate iodine in preparation for foetal pituitary 
TSH stimulation at approximately 20 weeks of gestation (Leung et al., 2011). During 
the second trimester, maternal iodine crosses to the placental unit allowing the foetal 
thyroid gland to produce thyroid hormones independently from the mother (Glinoer, 
2004).  
Due to these factors, dietary iodine requirements throughout pregnancy and lactation 
are higher than in non-pregnant, non-lactating adults (Delange, 2007). As displayed 
in Table 4, the WHO recommend approximately 10% more iodine per day for 
pregnant women (250 µg/day) compared to guidance set by the IoM (220 µg/day). 
There are currently no specific iodine recommendations for UK mothers during 
pregnancy and lactation (COMA, 1991). 




1.2.7 Iodine Assessments 
Two common assessments used to determine iodine status are urinary iodine 
concentration (UIC) and biomarker analysis (serum T4, TSH and thyroglobulin) 
(Zimmermann, 2009a). UIC determination is a good indicator of recent iodine status 
as approximately 90% of all dietary iodine intake is excreted from the body via urine. 
As a non-invasive procedure, urine samples are easy to obtain, with spot urines being 
the most commonly used due to their improved practicality over 24 hour urine 
collections (Zimmermann, 2012). There are several methods to assess UIC including 
colorimetric assays and inductively coupled plasma mass spectrometry (ICP-MS). 
Epidemiological criteria for UIC as set by the WHO is displayed in Table 5 (World 
Health Organisation, 2007). Both serum TSH and serum thyroglobulin are also used 
as markers of iodine status. TSH increases in response to a low circulating level of 
T4. TSH testing is effective in neonates, however less sensitive in children and adults. 
As thyroglobulin is a specific thyroidal protein, its assessment is a better indicator of 
iodine status in children and adults with an increase in blood thyroglobulin signalling 
a potential iodine deficiency (Zimmermann, 2009a). 
 
UIC (µg/L) Iodine Intake Iodine Status 












More than adequate 
Excessive 
 
Severe iodine deficiency 
Moderate iodine deficiency 
Mild iodine deficiency 
Adequate iodine deficiency 


























Children less than 2 









Table 5: The WHO UIC criteria. UIC criteria used to assess iodine nutrition in 
differing population groups. Criteria is based on median UIC status in school aged 




1.2.8 Iodine Deficiency 
Iodine Deficiency Disorders (IDD) are the manifestation of adverse clinical effects 
resulting from insufficient iodine intake and inadequate thyroid hormone production 
(Zimmermann, 2012). IDD are the “most common cause of preventable mental 
retardation and underdevelopment in the world” as defined by the WHO (World 
Health Organisation, 2007). The onset of IDD can vary depending on age as seen in 
Table 6. Pregnant and lactating women along with those under three years of age 
are important populations to monitor as iodine deficiency can be detrimental to long-





Increased perinatal morbidity and mortality 
Endemic cretinism 
Neonate Neonatal goitre 
Neonatal hypothyroidism 
Endemic neurocognitive impairment 
Increased susceptibility of the thyroid gland to nuclear 
radiation 
Child and adolescent Goitre 
(Subclinical) hypothyroidism 
Impaired mental function 
Retarded physical development 
Increased susceptibility of the thyroid gland to nuclear 
radiation 
Adult Goitre with its complications 
Hypothyroidism 
Impaired mental function 
Spontaneous hyperthyroidism in the elderly 
Iodine induced hyperthyroidism 
Increased susceptibility of the thyroid gland to nuclear 
radiation 
Table 6: Common IDD. Table 6 lists some of the common IDD seen in differing 




1.2.8.1 Iodine Deficiency during Pregnancy 
Iodine deficiency during pregnancy has been linked with goitre (Alexander et al., 
2017), congenital abnormalities, (Miller et al., 2016), endemic cretinism, spontaneous 
abortion and still birth (Arthur et al., 1999). Severe iodine deficient states give rise to 
low levels of circulating T4, causing the pituitary gland to stimulate production and 
secretion of TSH. The consequence of this continual, long-term TSH stimulation and 
low T4 results in the hyperplasia of the thyroidal follicular cells creating an enlarged 
maternal and foetal thyroid (goitre) (Ahad and Ganie, 2010; Alexander et al., 2017). 
With thyroid hormone receptors present in the foetal brain at 9 weeks, sufficient 
thyroid hormone concentrations are required for early myelination, normal neuronal 
migration and maturation of the foetal brain (Zimmermann, 2011). However, in iodine 
deficient states, insufficient thyroid hormone concentrations can cause severe brain 
damage and irreversible neurological abnormalities. This has the risk of manifesting 
as endemic cretinism in the offspring (Zimmermann, 2016). There are two forms of 
cretinism –neurological and myxoedematous. Neurological cretinism is characterised 
by deaf-mutism, motor spasticity of the limbs and mental retardation caused by 
impaired brain development (Ahad and Ganie, 2010). Myxoedematous is discussed 
in section 1.3. Whilst severe iodine deficiency in pregnancy has been well 
characterised, the effects of mild to moderate iodine deficiency are less conclusive 
(Hynes et al., 2013).  
1.2.9 Preventing Iodine Deficiency 
Iodination of dietary salt has been the main approach in combatting global iodine 
deficiency. Since 1994, the WHO, United Nations Children Fund (UNICEF) and the 
International Council for Control of Iodine Deficiency Disorders (ICCIDD) have 
recommended universal salt iodisation (USI) programmes be implemented in 
countries known to have populations at risk of severe and mild/moderate iodine 
deficiency (World Health Organisation, 2007). As of 2013, iodine fortification 
programmes were mandatory in 13 European countries, whilst 22 countries had yet 
to implement any legislation, including the UK (Lazarus, 2014). In countries that have 
implemented iodine fortification programmes, iodised salt is the main source of 
iodine, either from foods produced in mass industry or from household usage 
(Zimmermann and Andersson, 2012). For example, fortification of bread with iodised 




1.3 Iodine, Selenium and Thyroidal Interaction 
The thyroid contains the highest concentrations of iodine and selenium in the entire 
body (Wu et al., 2015). With the biological role of iodine only known to be implicated 
in thyroid hormone production, the interactions between the two micronutrients are 
pivotal for the synthesis and subsequent utilisation of thyroid hormone metabolism 
(Schomburg and Kohrle, 2008; Arthur et al., 1999). Two specific selenoprotein 
families have an influential effect on the thyroid hormone axis, GPx and DIO 
(Zimmermann and Kohrle, 2002). 
Essential for thyroid hormone metabolism (see section 1.1.5.3) (Ventura et al., 2017), 
DIO are implicated in the activation and deactivation of thyroid hormones (Arthur et 
al., 1999). Inadequate selenium intake witnessed in the study of rats first suggested 
that high T4 and low T3 concentrations was the result of inadequate DIO expression, 
resulting in the impaired conversion of T4 to T3 (Arthur et al., 1999). Selenium and 
iodine deficiency can therefore lead to abnormalities in thyroid hormone synthesis 
and limited hormone activation due to decreased DIO activity, thereby impacting 
negatively on growth and maturation (Arthur et al., 1999). Under selenium deficient 
states, the decrease in DIO1 specifically stimulates the HPT axis to increase TSH 
concentration as it has been shown that TSH significantly increases DIO1 activity 
(Beech et al., 1995). However, an increased stimulation of TSH in selenium and 
iodine deficient states can also affect the normal architecture of thyroid gland due to 
impaired GPx activity resulting from insufficient selenium. GPx3 is an abundant 
selenoprotein within the thyrocytes and is responsible for the neutralisation of H2O2 
(section 1.1.5.1). During hormone synthesis, the thyroid gland must produce enough 
H2O2 for iodination of the tyrosyl residues on the thyroglobulin protein. Any excess 
H2O2 concentrations are removed by GPx3 to prevent extensive oxidative damage to 
the components of the follicular cell i.e. DNA damage (Drutel et al., 2013). In iodine 
deficient states, T4 levels drop, hyper-stimulating TSH and the upregulation of thyroid 
hormone production. Consequently, this leads to an increase in H2O2. If whole body 
selenium is sufficient, high concentrations of GPx3 are present at the thyrocytes 
apical membrane to ensure the adequate defence of excess H2O2, preventing cell 
damage. However, in selenium deficient states (double iodine-selenium deficiency), 
a decrease in GPx3 means further oxidative damage from toxic lipid 




The manifestation of severe iodine and selenium deficiency has led to disease states 
such as myxoedematous cretinism (Rayman, 2018). Myxoedematous cretinism was 
first linked to both iodine and selenium deficiencies following the results from a study 
based in Zaire, Central Africa (Diplock et al., 1990). Characterised by severe 
hypothyroidism, stunted growth, delayed sexual maturation and myxoedema 
(Schomburg, 2011), this form of cretinism is less severe than neurological cretinism 
onset (Drutel et al., 2013). Thiocyanate overload from non-detoxified cassava 
inhibiting iodide trapping within the placenta and foetal thyroid has also been linked 
to the onset of this disease (Eastman and Zimmermann, 2018).  
Studies have confirmed that the severely impaired concentrations of both selenium 
and iodine directly effects thyroid hormone expression and activation. Wu et al. 
(2015) compared populations in two different counties of Shaanxi Province, China for 
thyroid disease based on their soil selenium status; the county of Ziyang had 
adequate soil selenium, Ningshan country had low soil selenium. The results showed 
that significantly less participants (18%) had thyroid disease in the adequate 
selenium county compared to that of the low selenium county (30.5%, p<0.001). In 
addition to this, participants in the lowest quintile (<47 µg/L selenium) had the highest 
prevalence of subclinical hyperthyroidism, overt hypothyroidism and enlarged 
thyroid, showing that the low selenium concentrations were probably insufficient for 
adequate selenoprotein expression needed for thyroid gland protection. A further 
study performed in 1992 in Zaire showed that after 50 µg selenium supplementation 
over two months, fT4 levels fell significantly, implying that increased DIO1 was 
accountable for these changes (Contempré et al., 1992).  
Whilst studies have looked at selenium, iodine and thyroidal interactions within the 
general population, research between selenium and iodine during pregnancy has not 





1.4 Study Aims 
A number of studies have shown that the UK is mild-moderately deficient in iodine 
throughout pregnancy (Snart et al., 2019; Public Health England, 2018; Bath et al., 
2015) Furthermore, the effects of iodine deficiency throughout gestation and its 
impacts on birth outcome have been extensively researched. With an important role 
in thyroid hormone metabolism and oxidative stress prevention, very limited research 
has assessed selenium status and its associated biomarkers throughout gestation. I 
hypothesise that within this study, selenium will decrease throughout pregnancy, 
selenium will be positively associated with both biomarkers and that selenium will 
have an impact on birth outcome.  
Therefore to investigate this hypothesis, I aim to fulfil the following objectives: 
1) Longitudinally quantify the levels of selenium, iodine and relevant biomarkers 
across pregnancy, giving an up to date assessment from a small cohort of 
women in the North of England. 
2) Investigate the relationship between serum selenium and its biomarkers; 
SEPP1 and GPx3 during pregnancy.  
3) Investigate the relationship between iodine and its biomarkers; fT3, fT4, TSH 
and thyroglobulin. 
4) Investigate the relationship between serum selenium and iodine and the four 
thyroid hormones (fT3, fT4, TSH and thyroglobulin) during pregnancy.  
5) Determine whether serum selenium is a reliable indicator of dietary selenium 
intake.  
6) Investigate the impact of selenium status on birthweight.  
The study has several novel aspects. It will be the first UK based project to observe 
the relationship between selenium and iodine and how these two micronutrients 
interact during pregnancy. Additionally, no previous study based within the UK has 
exclusively studied selenium concentration and its association with birthweight. 




 Methods and Materials 
2.1 Participants and Sample Collection 
2.1.1 Cohort Overview 
Samples used in this study were obtained from the Health & Iodine Status in Babies 
(HIBA) longitudinal cohort (Health Research Authority Ethics Reference Number: 
16/YH/0260; IRAS Ref: 204895 - Sheffield Research Ethics Committee, National 
Institute of Health Research). 70 mothers were recruited from August 2016 to 
November 2017 in Bradford, UK. Selenium, iodine and their respective biomarkers 
were monitored across pregnancy at 3 approximate time intervals; 13-15, 24- and 
36-weeks’ gestation (Figure 12). Women were approached at the sonography clinic 
at the Bradford Royal Infirmary where HIBA study information was given both verbally 
and in writing to those expressing an interest to enrol on the study (subject to meeting 
specific inclusion/exclusion criteria (Table 7)). Participants who met the criteria were 
invited back to a subsequent appointment at the Bradford Institute for Health and 
Research Clinical Research Facility where the study information was reiterated, 
participant queries answered and consent forms signed. Participants were made 
aware that they could withdraw at any point of the study. At the first visit (12/±3 
weeks), research nurses administered an initial questionnaire (section 2.1.2), took 
anthropometric measurements such as weight and height, conducted a thyroid 
assessment (section 2.1.3), collected dietary assessments (section 2.1.4) and 
collected blood and urine samples (sections 2.1.5 and 2.1.6 respectively). The 
subsequent two visits were performed either in the clinic or at home as preferred by 
the participant. If the target week could not be met, visits were held either three weeks 
before the target week or three weeks after the target week. Meetings not possible 
within the intended timeframe were missed; participants would go on to attend 
subsequent visits. Mothers were reimbursed with a £10 voucher for each visit 
attended, in addition to any travel expenses. 
All participant information was kept anonymous throughout the duration of the study. 
Identification was done by assigning each participant with a unique study number. 
Mother and baby records detailing information such as gestational age and birth 
weight was only accessed with prior consent. These records were used in the data 




2.1.1.1 Inclusion/Exclusion Criteria 
Prior to participants commencing the study, each mother needed to meet specific 
inclusion and exclusion criteria as seen in Table 7. 
Inclusion Exclusion 
Female Prior history of thyroid disease 
Confirmed as Pregnant at 9-15 
weeks 
Use of thyroid medication i.e. 
thyroxine 
Aged 18-40  
Able to give informed consent  
Healthy with no known family history 
of thyroid conditions.  
 
Table 7: HIBA inclusion and exclusion criteria at recruitment. 
2.1.2 Questionnaires  
A comprehensive questionnaire was administered to all participants at the first visit 
by the recruitment team in Bradford (see Appendix 1: HIBA Questionnaire Examples). 
It assessed in detail the demographic information of all mothers including 
background, household information, education and circumstances. Questions also 
focussed on health such as prior medical history, their current pregnancy and their 
general wellbeing. All subsequent study visits included a brief follow-up 
questionnaire.  
2.1.3 Anthropometric Assessments and Thyroid Inspection 
Anthropometric assessments of weight and height were taken at each of the three 
visits. Participants were asked to remove any footwear prior to height assessments. 
Heavy articles of clothing were removed prior to weight assessments. Height was 
recorded with legs straight, heels together and head within the Frankfurt Horizontal 
Plane. Weight was recorded by participants standing in the middle of electronic 
scales. Thyroid inspections were also performed. In brief, a steady pulse and signs 
of tremor was initially measured. Participants eyes were assessed for protrusion and 
lid lag. Signs of goitre on the neck were measured by eye, during which participants 
were asked to swallow water to assess movement. Palpation techniques were further 





2.1.4 Dietary Assessment 
24-hour dietary assessments were taken at each visit using the Medical Research 
Council funded myfood24 dietary tool (University of Leeds, 
https://www.myfood24.org/web/). The extensive food database allows users to track, 
monitor and analyse the nutritional intake of individuals both accurately and easily. 
By selecting specific foods and the portion sizes, this database calculates nutritional 
data such as energy intake (kcal), fat (g), carbohydrates (g) and 
micro/macronutrients. This information can then be interpreted for further data 
analyses. Participants were asked to recall the food they had consumed within the 
previous 24 hours. Food intake was recorded chronologically by inputting into the 
system the brand name/exact food or drink; failing that either a similar item from a 
different brand was selected or the food item was replicated using a recipe builder. 
Portion size was assessed by asking participants how much they had consumed of 
each item based on photographic guides, grams or pack sizes. Higher portion sizes 
were manually entered. Lastly, participants were asked to recall any drinks consumed 
either with meals or throughout the day. Additional comments were added at the end 
of the dietary recall e.g. bouts of vomiting. Food data was inputted using a tablet 
device. If this was unavailable, the diary was recorded on paper and entered online 
retrospectively. Food diaries were labelled using a unique identifier in the format 
‘HIBA01234Visit (‘01234’ representing the participant identifier; ‘Visit’ representing 
the visit number). 
2.1.5 Blood Collection and Processing  
At each of the three visits, 30mL intravenous blood samples were collected. In brief, 
red top serum Vacuette© tubes (Greiner Bio-One Ltd, UK) were used to collect whole 
blood from participants. After collection, coded samples were inverted and left to clot 
for at least 30 minutes. Samples were centrifuged at 4°C for 10 minutes. The top 
layer of serum was collected and aliquoted in duplicate. After processing, samples 
were stored at -80°C at the Bradford Royal Infirmary until shipment on dry ice to the 
University of Leeds. Samples were kept at -80°C prior to analysis. 
2.1.6 Urine Collection and Processing  
Urine samples were collected at each of the three visits. In brief, mid-stream urine 
was collected by participants into collection tubes (Medline Scientific, UK). Collected 
samples were aliquoted in duplicate and centrifuged for 10 minutes at 4°C. Samples 
were barcoded and stored at -80°C at the Bradford Royal Infirmary until shipment on 







Figure 12: HIBA recruitment timeline. Women were approached at the routine dating scan as per the set criteria (Table 7) and invited to participate 
in the study. Study visits were undertaken at ~13-15 weeks, ~24 weeks and ~36 weeks gestation. Questionnaires, anthropometric assessments, 
dietary evaluation and blood and urine samples were administered/collected at each visit. 
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fT3, fT4, TSH and Thyroglobulin Hormone Quanitification (Thyroid Hormones)
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2.2 Laboratory Procedures  
2.2.1 Inductively Coupled Plasma Mass Spectrometry 
ICP-MS is a robust technique which works using the high temperatures of a plasma 
torch with a mass spectrometer to determine elemental concentrations in chemical, 
environmental and biological samples. First used in the 1980’s, it has gained 
acceptance in the laboratory environment due to its low detection limits (parts per 
trillion) and high sample throughput (Wolf, 2005). Both UIC and serum selenium 
concentrations were determined using this method at the School of Earth and 
Environment, University of Leeds. (Thermo iCAP Q, Liverpool, UK). 
 
 
Figure 13: Schematic diagram of the ICP-MS.. Samples are introduced into the 
ICP-MS system via the autosampler. They are carried by the argon stream via a 
peristaltic pump to the nebulizer where it is converted from liquid to aerosol in the 
spray chamber. Aerosol from the spray chamber enters the plasma torch where it is 
atomised. Further travel through the torch causes atoms to absorb energy until they 
are eventually ionised. Ions are introduced into the mass analyser where they are 
separated based on their mass to charge ratio (m/z) (Wolf, 2005; Bazilio and 





2.2.1.1 Serum Selenium Method Development 
Serum selenium method development was based on the protocol from the ‘Centers 
for Disease Control and Prevention (CDC) Environmental Health Method: Laboratory 
Procedure Manual for Copper, Selenium and Zinc (DLS 3006.8-02)’. ICP-MS 
(Thermo iCAP Q, Liverpool, UK) was used for all analyses. Selenium was determined 
at mass-to-charge ratio (m/z) = 77 (77Se) and m/z = 78 (78Se). 80Se was not used due 
to significant interference from dimerization of argon from the plasma torch (40Ar40Ar). 
The instrument was run in kinetic energy discrimination mode using helium as a 
collision gas. Instrument performance was established before each use by tuning the 
instrument and running a quality control solution. Two external serum certified 
reference materials (CRM) with known concentrations of selenium were purchased 
from Seronorm™ (L1 Lot#: 1309438; L2 Lot#: 1309416) and used during assay 
development. Quantification limits were determined by running a blank sample for a 
total of six times to obtain an experimental quantification limit of 17.3 parts per billion 
(ppb). Repeatability was determined by running the external CRM for a total of six 
times to calculate the 95% CI.. Results showed the uncertainty at the 95% CI was 
3.63%. Reproducibility was determined by repeating the previous experiment 6 times 
over 4 days. Spike recoveries obtained a 98.9% recovery with a spike of +5 ppb and 
108% recovery with a spike of 50 ppb; within the 90-110% acceptable range. CRM 
results demonstrated that the method was acceptable to be taken forward for sample 
analysis.  
2.2.1.2 Serum Selenium Protocol  
Patient samples, calibration standards and quality controls were diluted 1:30 prior to 
analysis with diluent (10 µg/L gallium internal standard, 0.2% volume/volume double 
distilled nitric acid, 1% ethyl alcohol and 0.01% Triton X-100; all Sigma Aldrich, UK), 
deionised H2O and base serum (Lot# BRH1374677, Seralabs, West Sussex, UK) as 
per Table 8. Calibration standards were spiked with selenium at the following levels; 
30, 120, 210, 300, 1200, 2100 and 3000 ppb with a selenium standard (Lot# RT564, 
Sigma Aldrich, UK). Quality Controls (QC) were created in house by spiking selenium 
standard into base serum at 1500 ppb and 150 ppb (calculations not included). 
External QC material was provided from Seronorm™, UK (L1-2; Lot# 1309438 and 
1309416, respectively). For extra validation, study samples were run alongside 
samples with known selenium concentrations provided by the United Kingdom 







Table 8: Serum selenium sample preparation. Selenium samples were prepared as per the following table fresh on the day of analysis. Participant 
samples, QC samples and calibration standards and UK NEQAS were allowed to thaw to an ambient temperature prior to use. Samples were 




















4200 150 - - - - 150 - 
In House QC 4200 150 - - 150 - - - 
Calibration 
Standards 
4200 - 150 150 - - - - 
Serum Blank 4200 150 - 150 - - - - 
External QC 4200 150 - - - 150 - - 
Aqueous Blank 4200 300 - - - - - - 
UK NEQAS 
Samples 




2.2.1.3 Urinary Iodine Development and Analysis 
Details of the UIC development process using ICP-MS is detailed in Snart et al. 
(2019). The method to determine urinary iodine concentration was based on the 
accredited ‘CDC Ensuring the Quality of Urinary Iodine Procedures (EQUIP)’ 
protocol. Samples, calibration standards, and QC samples were diluted 1:10 prior to 
sample analysis with diluent (1% tetramethylammonium hydroxide, 0.01% Triton X-
100 and 10 µg/L tellurium (all Sigma Aldrich, UK)), deionised H2O and base urine as 
seen in Table 9. Sample concentrations were calculated against a urine matched 
standard calibration curve spiked with iodide at the following levels: 0, 5, 10, 40, 70, 
100, 400, and 800 µg/L (Sigma Aldrich, UK). Low, medium and high internal QC 
samples were set at iodine concentrations between 40-75 µg/L, 90-110 µg/L and 
>100 µg/L, respectively. External CRM Seronorm™ Trace Metal Urine L1 and CDC 
EQUIP participation were used as external validation measures. 
 
Table 9: Urinary iodine sample preparation. Urinary iodine samples were prepared 
as per the following table fresh on the day of analysis. Participant samples, QC 
samples and calibration standards were allowed to thaw to an ambient temperature 
























4000 500 - - - - 500 
In house 
QC 
4000 500 - - 500 - - 
Calibration 
Standards 
4000 - 500 500 - - - 
Urine 
Blanks 
4000 500 - 500 - - - 
External 
QC 




2.2.2 Enzyme Linked Immunosorbent Assay  
Enzyme Linked Immunosorbent Assays (ELISA) are a specific analytical tool used to 
detect levels of proteins, hormones and biomarkers. A derivative of 
radioimmunoassay, ELISA uses the immunological concepts of antigen/antibody 
complexes with an enzyme-linked signal generator in order to quantify target 
molecules (Crowther, 2009; Gan and Patel, 2013). Thyroid hormones and selenium 
biomarkers were quantified using pre-validated commercial ELISA kits  
2.2.2.1 Serum Glutathione Peroxidase 3 
Human serum GPx3 was quantified using a pre-validated ‘sandwich’ ELISA kit (Lot 
number: K4001805, Catalog #: AG-45A-0020YEK-KI01, Adipogen, Switzerland). 5 
kit constituents were prepared fresh on the day prior to analysis (human GPx3 
standard [64 ng/mL] for calibration standard preparation, wash buffer 1x, ELISA 
buffer 1x, detection antibody and horse radish peroxidase (HRP)-labelled 
streptavidin). Human GPx3 standard was reconstituted with 1 mL deionised water 
and thoroughly mixed prior to standard preparation. Standards were produced 
according to Table 10. Wash buffer 1x was produced by diluting wash buffer 10x, 10-
fold with deionised water. ELISA buffer 1x was produced by diluting ELISA buffer 
10x, 10-fold with deionised water. The detection antibody was diluted 1000-fold prior 
to analysis with 1x ELISA buffer and was not stored for future use. HRP-labelled 
streptavidin was reconstituted with 100 µL of ELISA Buffer 1x and thoroughly mixed. 
The reconstituted HRP-labelled streptavidin was further diluted 200-fold and used 
within the assay. Participant serum samples were centrifuged for 6 minutes at 4600 
rpm and diluted 1:1000 prior to loading with ELISA buffer 1x. 100 µL of standards 
and samples were loaded onto the plate as per the plate layout in duplicate and 
incubated with gentle shaking for 1 hour at 37°C. Following incubation, wells were 
aspirated and washed three times with wash buffer 1x using an automated plate 
washer (Aspect Scientific, Cheshire, UK). 100 µL of detection antibody was added to 
the empty plate and incubated with gentle shaking for 1 hour at 37°C. The wash step 
was repeated and 100 µL of diluted HRP-labelled streptavidin was added to the wells 
and left to incubate with gentle shaking for 1 hour at 37°C. The wash step was 
repeated and 100 µL of tetramethylbenzidine (TMB) was added to the empty wells 
and shielded from light for 20 minutes at room temperature. 50µL of stop solution 
was added to all wells and the plate was read using a spectrophotometer at 450nm 
(Thermo Fisher MultiSkan Go!, UK). Optical densities were proportionate to the 
amount of sample in each well. Mean values were calculated and the blank optical 




Standard Spike Solution 









400 400 32 
B Standard A 400 400 16 
C Standard B 400 400 8 
D Standard C 400 400 4 
E Standard D 400 400 2 
F Standard E 400 400 1 
G Standard F 400 400 0.5 
H - - 400 0 
Table 10: Standard concentrations for GPx3. Standards for the GPx3 calibration 
curve were produced between the concentration ranges of 0-32 ng/mL using ELISA 
buffer 1x as diluent. Samples were prepared fresh on the day and were not stored 
for future use.  
 
Standard Spike Solution 









400  50 
B Standard A 400 400 25 
C Standard B 400 400 12.5 
D Standard C 400 400 6.25 
E Standard D 400 400 3.125 
F Standard E 400 400 1.562 
G Standard F 400 400 0.781 
H - - 400 0 
Table 11: Standard concentrations for SEPP1. Standards for the  SEPP1 
calibration curve were produced between the concentration ranges of 0-50 ng/mL 
using the sample dilution buffer as diluent. Samples were prepared fresh on the day 





2.2.2.2 Serum Selenoprotein P 
Human serum SEPP1 was quantified using a pre-validated ‘sandwich’ ELISA kit 
(Cat#: EH1943, Lot: H1943C122, Wuhan Fine Biotech Co Ltd). Four constituents 
were prepared fresh on the day of analysis (calibration standards from lyophilised 
standard [50 ng/mL], 1x wash buffer, biotin-labelled antibody working solution and 
HRP-streptavidin conjugate). The 50 ng/mL lyophilised standard was reconstituted 
with 1mL sample dilution buffer and left for 10 minutes prior to thorough mixing. 
Standards were prepared as per Table 11. Wash buffer concentrate was diluted 1:25 
with deionised water to create 1x wash buffer. Both the biotin labelled antibody 
working solution and HRP-streptavidin conjugate were diluted 1:100 prior to use in 
the assay (120µL of solution into 11,880µL of antibody/ HRP-streptavidin conjugate 
dilution buffers, respectively). Prior to sample loading, the pre-coated plate was 
washed a total of 2 times with 350 µL of 1x wash buffer using an automated plate 
washer (Aspect Scientific, Cheshire, UK). Serum samples were centrifuged for 6 
minutes at 4600 rpm and diluted 1:1000 prior to loading. 100 µL of calibration 
standards and samples were loaded onto the plate in duplicate and incubated with 
gentle shaking for 90 minutes at 37°C. After incubation, the plate was washed 2 times 
with 350 µL of 1x wash buffer and tapped on absorbent paper to remove any excess 
buffer. 100 µL of 1:100 biotin-labelled antibody working solution was subsequently 
added to the plate and left to incubate with gentle shaking for 60 minutes at 37°C. 
After incubation, the plate was washed a further 3 times with buffer being left to soak 
in the wells for 1 minute between cycles. 100 µL of 1:100 HRP-streptavidin conjugate 
working solution was added to the plate and incubated with gentle shaking for 30 
minutes at 37°C. After incubation, the cover film was removed and washed 5 times 
with a 90 second soak in each well after each wash cycle. After the final aspiration, 
90 µL of TMB was added to each well and left to incubate for approximately 10 mins 
in darkness at 37°C. 50 µL of stop solution was added to stop the reaction and the 
plate was read immediately at 450nm by a spectrophotometer (Thermo Fisher 
MultiSkan Go!, UK). Optical densities were proportionate to the amount of sample in 
each well. Mean values were calculated and the blank optical density was subtracted 




2.2.2.3 Serum Free Thyroxine  
Human serum fT4 was quantified using a competitive ELISA kit (Lot number: X17-
302, Biovendor, Czech Republic) as per the product data sheet (Cat No: RCD015R). 
The majority of constituents within the kit were ready to use - two constituents 
required preparation (fT4 HRP conjugate and wash buffer). The HRP conjugate was 
diluted 1:50 before use in a glass vial and vortexed thoroughly before use. Wash 
buffer concentrate was diluted 1:10 prior to use with deionised water and inverted 
numerous times to make sure the concentrate was thoroughly mixed. Seronorm™ 
Immunoassay Lyo L1-3 (Lot’s# 1510466, 1510478, 1510479 respectively; 
Seronorm™, UK) was used as the external QC. Standard curve concentrations are 
listed in Table 12. Serum samples were centrifuged for 6 minutes at 4600 rpm prior 
to loading. 25 µL of standards, QC and participant samples were added into each 
well as per the plate layout in duplicate. 100 µL of HRP conjugate was added to each 
well and incubated at 37°C for 1 hour. After incubation, wells were washed 3 times 
with 300 µL of wash buffer using an automated plate washer (Aspect Scientific, 
Cheshire) and tapped to remove excess solution. 150 µL of TMB was added to the 
empty wells and left to incubate at 37°C. 50 µL of stop solution was added after 15 
minutes and the plate was read by the spectrophotometer at 450nm (Thermo Fisher 
MultiSkan Go!, UK). A 4-parameter logistical curve was used to interpret calibration 
and sample concentrations. 
 
 
Figure 14: ELISA assay completion.  The final step of the ELISA protocol ends the 
assay via the addition of sulphuric acid. The plate is then read at 450nm by the 
spectrophotometer where the optical densities are calculated for standards, QC 




2.2.2.4 Serum Free Triiodothyronine  
Human serum fT3 was quantified using a competitive ELISA kit (Lot number: X17-
303, Biovendor, Czech Republic) as per the product data sheet (Cat No: RCD014R). 
The majority of constituents within the kit were ready to use - two constituents 
required preparation prior to analysis (fT3 HRP conjugate and wash buffer). The HRP 
conjugate was diluted 1:50 before use in a glass vial and vortexed thoroughly before 
use. Wash buffer concentrate was diluted 1:10 prior to use with deionised water. 
Seronorm™ Immunoassay Lyo L1-3 (Lot’s# 1510466, 1510478, 1510479 
respectively, Seronorm™ UK) were used as an external QC. Standard curve 
concentrations are listed in Table 13. Serum samples were centrifuged for 6 minutes 
at 4600 rpm prior to loading. 25 µL of standards, QC samples and participant samples 
were added into each well as per the plate layout in duplicate. 100 µL of HRP 
conjugate was added to each well and incubated at 37°C for 1 hour. After incubation, 
wells were washed 3 times with 300 µL of wash buffer using an automated plate 
washer (Aspect Scientific, Cheshire) and tapped to remove excess solution. 150 µL 
of TMB was added to the empty wells and left to incubate at 37°C. 50 µL of stop 
solution was added after the15 minute incubation and read by the spectrophotometer 
at 450nm (Thermo Fisher MultiSkan Go!, UK). A 4-parameter logistical curve was 
used to interpret calibration and sample concentrations. 
 
 
Figure 15: HIBA cohort samples. Samples were thawed and centrifuged prior to 
analysis. Each sample was identified by a unique, seven digit number as seen in 
Figure 15. Samples were returned to the -80ºC freezer within a 2 hour window to 





2.2.2.5 Serum Thyroid Stimulating Hormone  
Human serum TSH was quantified using a competitive ELISA kit (Lot number: X17-
301, Biovendor, Czech Republic) as per the product data sheet (Cat No: RCD028R). 
The majority of constituents within the kit were ready to use - two constituents 
required preparation prior to use (TSH HRP conjugate and the wash buffer). The 
HRP conjugate was diluted 1:50 prior to use in a glass vial. Wash buffer concentrate 
was diluted 1:10 prior to use with deionised water. Seronorm™ Immunoassay Lyo 
L1-3 (Lot’s# 1510466, 1510478, and 1510479 respectively, Seronorm™ UK) was 
used as an external QC. Standard curve concentrations are listed in Table 14. Serum 
samples of the participants were centrifuged for 6 minutes at 4600 rpm prior to 
loading. 50 µL of standards, QC samples and participant samples was added into 
each well as per the plate layout in duplicate. 100 µL of HRP conjugate was added 
to each well and incubated at room temperature for 1 hour shaking at 400 rpm. After 
incubation, wells were washed 3 times with 300 µL of wash buffer using an automated 
plate washer (Aspect Scientific, Cheshire) and tapped to remove excess solution. 
150 µL of TMB was added to wells and left to incubate at room temperature for 15 
minutes, shaking at 400 rpm. 50 µL of stop solution was added after the 15 minute 
incubation and read by the spectrophotometer at 450 nm (Thermo Fisher MultiSkan 




Figure 16: Thermo Scientific MultiSkan GO! Spectrophotometer. Optical 
densities for each ELISA assay were quantified using the spectrophotometer at the 
end of each experiment. Results were exported and used for calculating calibration 











Table 12: Standard concentrations for fT4. Standards for the fT4 calibration curve 
were quantified between the concentration ranges of 0-80 pg/mL. Standards were 
pre-prepared and not stored after use. 
 
 







Table 13: Standard concentrations for fT3.Standards for the fT3 calibration curve 
were quantified between the concentration ranges of 0-40 pg/mL. Standards were 
pre-prepared and not stored after use. 
 
 







Table 14: Standard concentrations for TSH. Standards for the TSH calibration 
curve were quantified between the concentration ranges of 0-30 µIU/mL. Standards 





2.2.2.6 Serum Thyroglobulin 
Human serum thyroglobulin was quantified using a pre-validated commercial 
‘sandwich’ ELISA kit (Lot number: GR3221643, Abcam, UK). 5 kit constituents were 
prepared fresh on the day (calibration standards, 1x assay diluent B, 1x wash 
solution, 1x biotinylated thyroglobulin detection antibody and HRP streptavidin 
solution). Thyroglobulin lyophilised standard was reconstituted using 400 µL of assay 
diluent C before centrifugation to ensure thorough mixing. Standards were serially 
diluted as per Table 15. 1x assay diluent B was prepared by diluting 10 mL 5x assay 
buffer B into 40 mL deionised water. 25 mL of 20x wash buffer was diluted in 475 mL 
of deionised water to produce 1x wash solution. Prior to reconstituting the biotinylated 
thyroglobulin detection antibody, the vial was centrifuged to ensure all material was 
in the bottom of the tube. 100 µL of 1x assay diluent B solution was added and mixed 
gently using a pipette. This was then diluted 80-fold (150 µL into 11,850 µL using1x 
assay diluent B) and used within the assay. The HRP streptavidin concentrate was 
centrifuged and pipette mixed prior to use. For use in the assay, it was diluted 600-
fold (20 µL into 11,980 µL of 1x assay diluent B). Serum samples were centrifuged 
for 6 minutes at 4600 rpm prior to loading onto the plate. 100 µL of standards, 
samples and QCs were added onto the plate as per the plate layout and incubated 
with gentle shaking for 2.5 hours at room temperature. Following incubation, wells 
were washed using an automated plate washer (Aspect Scientific, Cheshire) 4 times 
with 300 µL of 1x wash solution. The plate was tapped on absorbent paper to remove 
any excess solution. 100 µL of 1x biotinylated thyroglobulin detection antibody was 
added into each well and incubated with gentle shaking for 1 hour at room 
temperature. Following further washing (as described above), 100 µL of HRP-
streptavidin solution was added to each well and incubated with gentle shaking for 
45 minutes at room temperature. Following the final wash step, 100 µL of TMB 
solution was added to all wells and incubated with gentle shaking for 30 minutes at 
room temperature shielded from light. 50 µL of stop solution was added in the final 
step to stop the reaction. The plate was read using a Spectrophotometer (Thermo 
Fisher MultiSkan Go!, UK). Mean values were calculated and the blank optical 





Table 15: Standard concentrations for thyroglobulin. Standards for the 
thyroglobulin calibration curve were quantified between the concentrations ranges of 
0-50 ng/mL and prepared fresh on the day. Standards were not stored for future use.  












- 400 50 
B Standard A 200 300 20 
C Standard B 200 300 8 
D Standard C 200 300 3.2 
E Standard D 200 300 1.28 
F Standard E 200 300 0.512 
G Standard F 200 300 0.205 




2.3 Statistical Analysis 
Statistical analysis was performed using STATA Standard Edition v13.1. 
Questionnaire data, dietary data and biomarker concentration databases from the 
first three time points (~13-15 weeks, ~24 weeks and ~36 weeks) were imported and 
merged from Microsoft® Excel. Prior to correlation and regression analysis, all 
biomarkers were assessed for normality using histogram plots and Schapiro-Wilks 
analysis (results and plots not displayed). Biomarkers that did not have a normal 
distribution had corresponding concentrations log transformed before further 
analysis. Differences of the mean were assessed using either an independent t-test 
or Mann Whitney-U test (depending on distribution). Pearson’s correlation was used 
to assess linear relationships between the following variables: 
1. Serum selenium and GPx3/SEPP1/iodine/TSH/fT3/fT4/thyroglobulin/dietary 
selenium and birthweight 
2. Iodine and fT4/fT3/TSH and thyroglobulin.  
Moving average plots were created in GraphPad Prism v7.0 to track mean 
concentrations over time. One-way repeated measure ANOVA with Greenhouse-
Geisser correction was performed in STATA to test for significant changes over time. 
This method was used to take into consideration that several concentration 
measurements were taken within-individual at differing time points. Significance is 
indicated if there are differences in concentration between at least two of the time 
points. Sphericity assumes variance of the differences between-visits are constant, 
however, in this instance, the requirement was not met. To take into account this 
violation, Greenhouse-Gessier correction was used for all results generated from the 
ANOVA. fT3/fT4 ratios were determined by calculating mean values of fT3, dividing 
them by the mean values of fT4. This ratio will determine the normal functioning of 
the DIO. Repeated measures linear regression with and without adjustment for 
confounders (age, smoking, body mass index (BMI), alcohol consumption, all 
supplementation usage, ethnicity and where applicable, UIC and selenium) was 
performed in STATA to model associations between variables. We were able to take 
into account the repeated measures using a sandwich estimation allowing for the 
similarity of results ‘within-person’ and any possible heteroscedasticity. All results are 






3.1 Maternal Characteristics 
Participant demographics were collated using the questionnaire data (see section 
2.1.2) and are displayed in Table 16. The mean (standard deviation (SD)) age of the 
women in the study was 30 (5.8) years. Average weight and BMI increased 
consistently throughout trimesters with a 9.8 kg increase and a 4 kg/m2 increase from 
visit one to visit three, respectively. For 37% of the mothers, this was their first 
pregnancy. Just over half of the women were Pakistani and 35.7% were White-
British. Either one or two women reported smoking and alcohol consumption at each 
visit (1.4-2.9%). Vitamin supplementation was extremely high, peaking at the first visit 
with 97.1%. 79.4% of these supplements taken at this time point were multivitamins 





 n Mean (SD) 
Maternal Age (years) 69 30.4 (5.8) 
Maternal Weight (kg) 
 1st Visit 
 2nd Visit 









Maternal Height (cm) 65 160.4 (7.0) 
BMI (kg/m2) 
 1st Visit 
 2nd Visit 



































 1st Visit 
 2nd Visit 





















Alcohol Consumption (%) 
 1st Visit 
 2nd Visit 









Vitamin Supplementation (%) 
 1st Visit 
 2nd Visit 









Table 16: Maternal characteristics. Descriptive statistics of the women used within 
the analysis. Continuous variables are reported as Mean (SD) and categorical 
variable are reported as n (%) 1Other Ethnicities include Bangladeshi, Indian, Polish 
and Romanian. Total sample size = 70. Small amounts of missing data accounts for 




3.2 Ethnicity Analysis 
The bi-ethnic cohort allowed for a small analysis of the two main ethnic groups 
(White-British and Pakistani) to determine differences in selenium, iodine and their 
corresponding biomarker concentrations. The median concentration (interquartile 
range (IQR)) of each biomarker across all three time points are displayed in Table 
17. Only iodine status was found to be significantly different between the two groups.  
 
Biomarker White-British Pakistani 
Selenium (µg/L) 64.9 (15.3) 63.6 (14.1) 
Iodine (µg/L)*^ 88.9 (120)*^ 132.2 (144)*^ 
SEPP1 (ng/mL) 3784 (1144) 4017 (1018) 
GPx3 (ng/mL) 6972 (2382) 6776 (1712) 
fT3 (pg/mL) 2.3 (0.66) 2.1 (1.26) 
fT4 (pg/mL) 8.7 (3.07) 8.7 (2.70) 
TSH (µIU/mL) 1.4 (0.85) 1.2 (1.12) 
Thyroglobulin (ng/mL) 5.1 (6.80) 3.7 (11.4) 
Table 17: Biomarker concentrations by ethnicity. Median (IQR) values for each 
biomarker is shown in the table above. Independent t-tests were performed on 
normally distributed data (iodine and thyroglobulin not normally distributed - Mann 





3.3 Selenium, Glutathione Peroxidase 3 and Selenoprotein P  
Table 18 shows the median (IQR) values at each visit for the three listed biomarkers. 
Whilst median serum selenium and GPx3 concentrations were seen to fall throughout 
pregnancy (from 71.4 to 57 µg/L selenium; 7076 to 6443 ng/mL GPx3), SEPP1 
concentrations increased steadily from 3750 µg/L in visit one to 4300 ng/mL in visit 
three. 94.2% of individuals were below the 90 µg/L selenium threshold for optimal 
GPx3 expression at the first visit - this value increased to 100% of participants at the 
third visit (Thomson et al., 1977). Figure 17 and Figure 18 shows the relationship 
between selenium and the selenium containing enzymes, GPx3 and SEPP1. In 
Figure 17, GPx3 was found to be positively correlated with serum selenium 
concentration across all three visits. Pearson’s correlation was performed at each 
individual time point (Fig 17, A-C) and for all visits (Fig 17, D) with results confirming 
a moderate relationship between the two biomarkers (Pearson’s correlation 
coefficient Graph D:, rp=0.59, 95% CI 0.49 to 0.67, p<0.001). Plots showing the mean 
values (with 95% CI) for GPx3 and selenium at each visit are displayed in Graphs E 
and F. A decreasing trend in concentrations of GPx3 and serum selenium is apparent 
as gestation progresses. For both biomarkers, a one-way repeated measure ANOVA 
with Greenhouse-Geisser correction was performed. It was found that throughout 
pregnancy, decreases in selenium (F [2,137] = 92.02, p<0.001) and GPx3 (F [2, 138] 
= 23.35, p<0.001) were statistically significant. Using adjusted and unadjusted repeat 
measure linear regression models (Table 23), GPx3 was found to be significantly 
associated with serum selenium status during pregnancy (p<0.001 both unadjusted 
and adjusted for age, smoking, BMI, alcohol consumption, supplementation usage 
and ethnicity). For every 1 µg/L increase in serum selenium, there was a 68 ng/mL 
increase in GPx3 concentration (β = 68, 95% CI 50.1 to 88.0). SEPP1 was negatively 
correlated with serum selenium (Figure 18) across the duration of pregnancy (Fig 18, 
A-D). Pearson’s correlation was performed for all visits (Fig 18, D) with results 
confirming a weak to moderate negative relationship (Pearson’s coefficient rp= -0.32, 
95% CI -0.44 to -0.20, p<0.001). The moving average plot as seen in Graph E clearly 
shows a mean rise in SEPP1 concentration from visit 1 to visit 3 and this was 
statistically significant as per one-way repeated measure ANOVA with Greenhouse-
Geisser correction (F [2,132] = 30.57, p<0.001). Using unadjusted and adjusted 
repeat measure linear regression models, serum selenium was found to be a 
negative predictor of SEPP1 (p<0.001). For every 1 µg/L increase in serum selenium, 













Serum selenium (µg/L) 71.4 (16.4) 64.2 (12.2) 57.7 (15.3) 
Urinary iodine (µg/L)* 103.4 (118.4)  120.8 (116.6)] 112.1 (177.5) 
Glutathione peroxidase 3 (ng/mL) 7076.0 (1865.0) 6811.6 (2050.1) 6443.3 (2143.5) 
Selenoprotein P (ng/mL) 3749.5 (1016.4) 3761.2 (925.2) 4299.3 (940.3) 
TSH (µIU/mL) 1.12 (0.9) 1.35 (1.0) 1.53 (0.9) 
fT4 (pg/mL) 9.7 (2.8) 8.2 (2.6) 8.2 (3.4) 
Thyroglobulin (ng/mL) 5.6 (10.2) 4.3 (9.4) 4.6 (12.7) 
fT3 (pg/mL)  2.4 (0.9) 2.0 (0.8) 2.1 (2.4) 
Table 18: Median biomarker concentrations. Serum selenium, urinary iodine, GPx3, SEPP1, TSH, fT4, fT3 and thyroglobulin concentrations by 






Figure 17: Correlations and moving averages for selenium and GPx3. Graphs 
A-C show the relationship between serum selenium and GPx3 across each visit 
(rp=0.45, 0.63 and 0.61, p<0.001 for all visits, respectively). Graph D shows the 
combined correlation of all visits throughout pregnancy (p<0.001). Graphs E and F 







Figure 18: Correlations and moving averages for selenium and SEPP1. Graphs 
A-C show the relationship between serum selenium and SEPP1 across each visit 
(rp= -0.22, -0.22 and -0.31, p<0.001 for visit 3 only). Graph D shows the combined 
correlation of all visits throughout pregnancy (p<0.001). Graphs E and F show the 
mean change over time with 95% CI plotted for each time point. 
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3.4 Urinary Iodine and Thyroid Hormone Associations 
Median (IQR) concentrations for iodine, fT4, fT3 TSH and thyroglobulin at each visit 
is displayed in Table 18. Median iodine concentrations fluctuated throughout 
pregnancy, remaining consistently below the 150µg/L threshold set by the WHO for 
UIC during pregnancy. Median TSH levels increased throughout gestation (1.12 
µIU/mL to 1.53 µIU/mL), whereas median fT4, thyroglobulin and fT3 decreased from 
visit one to two. Levels plateaued at the third visit for fT4 and fT3 whilst median 
thyroglobulin levels increased at the last visit from 4.3(9.4) ng/mL at visit two to 
4.6(12.7) ng/mL at visit three. Figure 19 depicts the strength of the relationships 
between iodine and each corresponding thyroid hormone. Pearson’s correlation was 
performed for fT3 (rp= -0.07, 95% CI -0.20 to 0.07, p=0.36), fT4 (rp= 0.08, 95% CI -
0.06 to 0.22, p=0.24), TSH (rp= 0.07, 95% CI -0.07 to 0.21, p= 0.31) and thyroglobulin 
(rp=-0.14, 95% CI -0.27 to 0.003, p=0.06). Results indicated that there was no 
relationship between iodine and fT3, fT4 and TSH; however there was a weak inverse 
relationship between iodine and thyroglobulin that was very close to statistical 
significance (p=0.06). Repeat measures linear regression analysis was performed to 
determine associations between iodine and all four thyroid hormones (Table 19). 
After adjustment for confounding with age, ethnicity, smoking, BMI, serum selenium 
concentration, alcohol consumption and vitamin supplementation; no significant 
associations were found. 
 Adjusted Estimates 
Iodine 
β coefficient  
(CI 95%) 
p value 
fT3 (pg/mL) 0.95 (0.82 to 2.33)  0.48 
fT4 (pg/mL) 1.40 (0.85 to 2.33)  0.19 
TSH (µIU/mL) 1.03 (0.87 to 1.24) 0.67 
Thyroglobulin (ng/mL) 0.94 (0.72 to 1.25) 0.70 
Table 19: Iodine and thyroid hormone regression analysis. Beta coefficients, 
95% CI and p-values after repeat measure linear regression between iodine and its 
corresponding biomarkers. Results for all biomarkers are presented as a ratio due to 








Figure 19: Correlations between iodine and the thyroid hormones. Graphs A-D show the relationship between iodine and fT3 (Graph A), fT4 
(Graph B), TSH (Graph C) and thyroglobulin (Graph D) across all time points throughout pregnancy. 
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3.5 Serum Selenium and Thyroid Hormone Associations 
Serum selenium concentration was correlated against each thyroid hormone as seen 
in Figure 20, Figure 21, Figure 22 and Figure 23. fT3, fT4 and TSH were found to be 
normally distributed. Thyroglobulin was found not to be normally distributed therefore 
data for this biomarker was log transformed prior to regression analysis. In each of 
the figures, Graphs A-C depict selenium and its correlation with each thyroid hormone 
at visits one to three. Graph D shows selenium concentration with each biomarker 
for all 70 participants at all visits. Pearson’s correlation using all time points was 
calculated for all hormones (Graph D). fT3 (rp= 0.06, 95% CI -0.08 to 0.19, p=0.41) 
and TSH (rp= -0.08, 95% CI -0.21 to 0.06, p=0.27) did not show a relationship with 
selenium. fT4 (rp= 0.13, 95% CI -0.01 to 0.26, p=0.07), and thyroglobulin (rp= 0.12, 
95% CI -0.03 to 0.26, p=0.12) displayed a small positive correlation with serum 
selenium concentration, however no result was statistically significant. Moving 
average plots with 95% CI (Graphs E) mimic the trends seen in Table 18. Wide 
confidence intervals as seen for thyroglobulin and TSH are indicative of a small 
population size and are normal given the study design. One way repeated measure 
ANOVA with Greenhouse-Geisser correction was performed to test for significant 
differences between at least two of the mean values for each hormone. A significance 
difference in mean concentration for all hormones was found, except for thyroglobulin 
(Table 20). Table 21 shows the ratios between fT3 and fT4 at each visit. Results 
demonstrated that across pregnancy, the concentrations of the thyroid hormones 
remained consistent. This indicates that DIO expression was sufficient for the 
conversion of fT4 to fT3  
Repeat measure linear regression was performed for all four thyroid hormones. Beta 
coefficients, confidence intervals and p values are displayed in Table 22. As 
thyroglobulin was not normally distributed, beta coefficients are displayed as a ratio. 
Adjusting for age, smoking, BMI, alcohol consumption, UIC, supplementation usage 
and ethnicity, analysis showed that serum selenium concentration was not a 
statistically significant predictor of fT3 (β= 0.008, CI 95% -0.01 to 0.02, p=0.31), fT4 
(β= 0.03, CI 95% -0.02 to 0.08 p=0.23), TSH (β= 0.005, CI 95% -0.01 to 0.02, p=0.52) 
and thyroglobulin (β= 1.01, CI 95% 0.99 to 1.03, p=0.30). For every 1µg/L increase 
in serum selenium, there were minimal increases in concentrations of fT3 (0.008 






Figure 20: Correlations and moving averages for selenium and fT3. 
Graphs A-C show the relationship between selenium and fT3 across each visit 
(rp= -0.09, 0.02 and -0.02, p>0.05 for all visits, respectively). Graph D shows 
the combined correlation of all visits throughout pregnancy (rp=0.05, p=0.41). 
Graphs E and F display how mean fT3 and selenium concentrations change 






Figure 21: Correlations and moving averages for selenium and fT4. 
Graphs A-C show the relationship between selenium and fT4 across each visit 
(rp= 0.15, -0.10 and -0.004, p>0.05 for all visits, respectively). Graph D shows 
the combined correlation for all visits throughout pregnancy (rp=0.13, p=0.07). 
Graphs E and F show how mean fT4 and selenium concentrations change over 







Figure 22: Correlations and moving averages for selenium and TSH. Graphs A-
C show the relationship between selenium and TSH across each visit (rp= 0.09, 0.07 
and 0.004, p>0.05 for all visits, respectively). Graph D shows the combined 
correlation of all visits throughout pregnancy (rp=-0.08, p=0.27). Graphs E and F show 
how mean TSH and selenium concentrations change over time with 95% CI plotted 




Figure 23: Correlations and moving averages for selenium and thyroglobulin. 
Graphs A-C show the relationship between selenium and thyroglobulin across each 
visit (rp= 0.08, 0.11 and -0.05, p>0.05 for all visits, respectively). Graph D shows the 
combined correlation for all visits throughout pregnancy (rp=0.07, p=0.32). Graphs E 
and F show how the mean concentrations of thyroglobulin and selenium changes 








Table 20: One-way repeated ANOVA for thyroid hormones. Results from the one-
way repeated ANOVA analysis for all four thyroid hormones indicate that a 
statistically significant difference in concentrations was witnessed over gestation. 
 
 




Table 21: fT3/fT4 ratios. fT3/fT4 ratios are displayed for each visit. There were no 
fluctuations in ratios as gestation progressed.  
Thyroid Hormone 
One way repeated measure ANOVA with 
Greenhouse-Geisser  
([dftime,dfresidual]=F, p value) 
fT3 F(2,138)=19.00, p<0.001 
fT4 F(2,130)=13.08, p<0.001 
TSH F(2,133)=30.01, p<0.001 









Unadjusted Estimates Adjusted Estimates 
 β coefficient (CI 95%) p value β coefficient (CI 95%) p value 
GPx3 (ng/mL) 79 (60.0 to 99.0) <0.001 68 (48.5 to 87.8) <0.001 
Selenoprotein P (ng/mL) -24 (-32.5 to -16.2) <0.001 -25 (-36.7 to -13.3) <0.001 
Iodine (µg/L)* 1.007 (1.00 to 1.02) 0.21 1.005 (0.99 to 1.02)  0.40 
fT4 (pg/mL) 0.03 (-0.01 to 0.07)  0.12 0.03 (-0.02 to 0.08) 0.23 
fT3 (pg/mL) 0.004 (-0.01 to 0.02) 0.55 0.008 (-0.01 to 0.02) 0.31 
TSH (µIU/mL) -0.005 (-0.02 to 0.01) 0.52 0.005 (-0.01 to 0.02) 0.52 
Thyroglobulin (ng/mL)* 1.01(1.00 to 1.03) 0.15 1.01 (0.99 to 1.03) 0.30 
Table 22: Repeat measure linear regression with selenium. Results show beta coefficients, 95% CI and p-values after repeat measure linear 
regression with GPx3, SEPP1, iodine, fT4, fT3, TSH and thyroglobulin. Adjusted estimates included age, smoking, alcohol consumption, BMI, 
ethnicity and vitamin supplementation for all variables. fT3, fT4, TSH and thyroglobulin was additionally adjusted for UIC. *Thyroglobulin and iodine 




3.6 Serum Selenium and Urinary Iodine Associations 
Figure 24 depicts the relationships between urinary iodine and serum selenium 
concentrations at each study visit (Fig 24, A-C). Urinary iodine and serum selenium 
concentrations were used to conduct a Pearson’s correlation. Using 207 
observations across all three time points (Fig 24, D), the Pearson’s coefficient was 
calculated as rp= 0.11, CI 95% -0.03 to 0.25, p=0.11; indicating a non-significant small 
positive relationship between the two biomarkers. The moving average plot for iodine 
is shown in Figure 24, Graph E. At visits 1, 2, and 3, the mean concentration totalled 
160.9, 145.1 and 169.8 µg/L, respectively. The variability in these concentrations is 
shown on the plots by the wide standard deviation, indicative of a small sample size. 
One-way repeated measure ANOVA with Greenhouse-Geisser correction was 
performed to indicate any significance between the differences of mean 
concentrations across visits. Results indicated that there was no significant difference 
in the means for iodine (F [2,136] =0.74, p=0.46). Table 22 shows the results from 
the unadjusted and adjusted repeat measure linear regressions with urinary iodine 
and serum selenium. As iodine was not normally distributed, data was log-
transformed and beta coefficients displayed as a ratio. Both unadjusted and adjusted 
linear regression models show that selenium was not a statistically significant 
predictor of iodine concentration. A 1 µg increase in selenium resulted in a 0.7% 
increase in iodine concentration (β= 1.007, 95% CI 1.00 to 1.02, p=0.21,) without 
adjustment for confounding. A 0.5% increase in iodine concentration with 1 µg rise in 
selenium was calculated with adjustments for age, smoking, BMI, alcohol 
consumption, supplementation usage and ethnicity (β= 1.005, 95% CI 0.99 to 1.02, 
p=0.40).  
To explore potential synergy (statistical interaction) between selenium and iodine 
levels and their relationships with thyroid hormones, participants were divided into 
two groups for both selenium and iodine. This was determined by calculating whether 
participants’ values were above or below the median level. Those in the ‘high’ groups 
had concentrations above the median, those participants in the ‘low’ group had 
concentrations below the median. This gave rise to four groups: ‘high’ in both 
selenium and iodine, ‘low’ in both selenium and iodine, ‘high’ iodine but ‘low’ selenium 
and ‘high’ selenium but ‘low’ iodine. Median concentrations for GPx3, SEPP1, fT3, 





Results are displayed in Table 23. Whilst most biomarkers showed little variation 
between the groups, there was some evidence that GPx3 was particularly low in 
mothers who had ‘low’ selenium and ‘low’ iodine compared to those mothers that had 
‘high’ selenium and ‘high’ iodine (5800 µg/L vs 7400 µg/L respectively). An opposite 
pattern showing increasing thyroglobulin between the same two groups (6.9 ng/mL 
vs 4.5 ng/mL) was also observed. 
 
Table 23: Iodine and selenium interactions. Table 22 shows the median values of 
each biomarker as per the high/low iodine and selenium groups. 1(ng/mL), 2(pg/mL), 
3(µIU/mL) 
  Selenium 







GPx31 5800 GPx31 7500 
SEPP11 4000 SEPP11 3600 
fT32 2.1 fT32 2.2 
fT42 8.3 fT42 8.3 
TSH3 1.4 TSH3 1.1 




SEPP11 4200 SEPP11 3800 
fT32 2.2 fT3
2 2.1 
fT42 9.0 fT42 8.8 






Figure 24: Correlations and moving averages for selenium and iodine. Graphs 
A-C show the relationship between selenium and iodine across each visit (rp= 0.20, 
0.14 and 0.20, p>0.05 for all visits, respectively). Graph D shows the combined 
correlation for all visits throughout pregnancy (rp=0.11, p=0.10). Graphs E and F 
show how the mean concentrations of iodine and selenium concentrations change 








3.7 Dietary Selenium and Serum Selenium 
The relationship between dietary selenium intake and serum selenium for each visit 
is depicted by Figure 25. Dietary selenium intake was quantified for each individual 
at each visit using the myfood24 tool (see section 2.1.4). Pearson’s correlation using 
dietary selenium values and serum selenium was used to generate a Pearson’s 
coefficient at visit 1 (Fig 25, A - rp=0.14, 95% CI -0.10 to 0.36, p=0.25). Visit 2 (Fig 
25, B) gave a result of rp=-0.01, 95% CI -0.25 to 0.22, p=0.92 and visit 3 (Fig 25, C) 
produced a coefficient of rp=0.11, 95% CI -0.1 to 0.33, p=0.37. A combined coefficient 
covering all visits (Fig 25, D) was rp=0.03, 95% CI -0.10 to 0.2, p=0.62. The results 
show that during visit 3, there was a very weak, positive correlation between serum 
selenium and dietary selenium. Correlation analysis with serum selenium at visits 1 
and 2 and with all visits combined (Graph D) showed no relationship. None of the 
results were statistically significant. 
Repeat Measure linear regression was performed to investigate whether dietary 
selenium was a significant predictor of serum selenium status. Unadjusted results 
(β=0.02, 95% CI -0.06 to 0.93, p=0.64) and results adjusted for age, ethnicity, 
smoking, alcohol consumption, BMI and vitamin supplementation (β=-0.01, 95% CI -
0.10 to 0.071, p=0.76) showed that dietary selenium was not a significant predictor 
of serum selenium status. For every 1 µg of dietary selenium consumed, there was 
a 0.02 µg/L increase in serum selenium (unadjusted regression model, not 
statistically significant). However, when adjusted for confounding, results displayed 
a slight decrease in serum selenium levels (-0.01 µg/L decrease in serum selenium 








Figure 25: Relationship between dietary selenium intake and serum selenium concentration. Graphs A-C show the relationship between 




3.8 Serum Selenium, Glutathione Peroxidase 3 and 
Selenoprotein P and their Associations with Birthweight  
Figure 26 depicts the relationships between serum selenium levels and birthweight 
for the 70 participants at each visit (Fig 26, A-C) and combined for all visits (Fig 26, 
D). Using the normally distributed data, a Pearson’s correlation was performed. The 
Pearson’s coefficient for visit one was calculated as rp=0.24, 95% CI -0.010 to 0.463, 
p=0.06, with visit two and visit three having coefficients of rp=0.008, 95% CI -0.240 
to 0.255, p=0.949 and of rp=-0.057, 95% CI -0.301 to 0.193, p=0.656, respectively. 
At visit one, there was a weak positive relationship with selenium and birthweight 
which was slightly above the statistical significance threshold (p=0.06). The 
remaining two visits throughout pregnancy showed no correlation. The overall 
coefficient for all combined visits was of rp=0.06, CI 95% -0.086 to 0.200, p=0.43 (Fig 
26, D) signifying no overall association between birthweight and selenium 
concentration throughout the entirety of pregnancy.  
Table 24 shows the results from the unadjusted and adjusted repeat measure linear 
regressions between selenium and birthweight at each visit. Serum selenium was 
found to be a significant predictor of birthweight at visit one. For every 1 µg increase 
in selenium concentration during the first visit, birthweight significantly increased by 
15 g; (results adjusted for age, ethnicity, smoking, alcohol consumption, UIC, BMI 
and vitamin supplementation, β=15, CI 95% 2 to 30, p=0.02). However, at visits two 
and three, selenium was not a significant predictor of birthweight (β= -4, 95% CI -20 
to 10, p=0.67 and β=2, 95% CI -10 to 20, p=0.77 respectively). GPx3 follows a similar 
trend to that of selenium (Table 25). Unadjusted and adjusted repeat measure linear 
regressions showed that GPx3 was a significant predictor of birthweight at the first 
visit; a 0.11g increase in birthweight was witnessed for each 1 ng increase in GPx3 
(β=0.11, CI 95% 0.009 to 0.2, p=0.032). However, no such associations were found 
during the later trimesters (p=0.776 and p=0.263 for visits two and three respectively). 
SEPP1 and its associations with birthweight can be seen in Table 26. Unlike GPx3 
and serum selenium, SEPP1 has a significant inverse association with birthweight at 
visits one and two (adjusted results β= -0.18, 95% CI -0.31 to -0.05, p=0.008 and β= 
-0.25, 95% CI -0.40 to -0.09, p=0.002, respectively). For every 1 ng increase in 
SEPP1, there was a decrease in birth weight by 0.18 and 0.25 g for visits one and 
two, respectively. SEPP1 was found not to be a significant predictor of birthweight 








Figure 26: Relationship between selenium concentration and birthweight. Graphs A-C show the relationship between serum selenium and 








Unadjusted Estimates Adjusted Estimates 
Birthweight (g) Β coefficient (CI 95%) p value Β coefficient (CI 95%) p value 
Visit 1 14 (0.4 to 30) 0.04* 15 (2 to 30) 0.02* 
Visit 2 0.4 (-10 to 20) 0.95 -4 (-20 to 10) 0.67 
Visit 3 -3 (-20 to 10) 0.60 2 (-10 to 20) 0.77 
All Visits 2 (-5 to 10) 0.45 4 (-5 to 10) 0.34 
Table 24: Repeat measure linear regression between selenium and birthweight. Beta coefficients, 95% CI and p-values generated from repeat 
measure linear regression between selenium and birthweight. Adjusted estimates included age, smoking, alcohol consumption, BMI, ethnicity, UIC 









Unadjusted Estimates Adjusted Estimates 
Birthweight (g) Β coefficient (CI 95%) p value Β coefficient (CI 95%) p value 
Visit 1 0.1 (0.01 to 0.18) 0.019* 0.11 (0.009 to 0.2) 0.032* 
Visit 2 0.01 (-0.073 to 0.10) 0.745 0.02 (-0.10 to 0.14) 0.776 
Visit 3 -0.06 (-0.16 to 0.04) 0.269 -0.05 (-0.15 to 0.04) 0.263 
All Visits 0.01 (-0.06 to 0.09) 0.702 0.02 (-0.07 to 0.10) 0.420 
Table 25: Repeat measure linear regression between GPx3 and birthweight. Beta coefficients, 95% CI and p-values after repeat measure linear 
regression between GPx3 and birthweight. Adjusted estimates included age, smoking, alcohol consumption, BMI, ethnicity, UIC and vitamin 









Unadjusted Estimates Adjusted Estimates 
Birthweight (g) Β coefficient (CI 95%) p value Β coefficient (CI 95%) p value 
Visit 1 -0.14 (-0.28 to 0.02) 0.087* -0.18 (-0.31 to -0.05) 0.008* 
Visit 2 -0.24 (-0.38 to -0.09) 0.002* -0.25 (-0.40 to -0.09)  0.002* 
Visit 3 -0.11 (-0.30 to 0.09) 0.274 -0.09 (-0.28 to 0.11)  0.385 
All Visits -0.14 (-0.27 to -0.004) 0.043* -0.18 (-0.30 to -0.06) 0.005* 
Table 26: Repeat measure linear regression between SEPP1 and birthweight. Beta coefficients, 95% CI and p-values after repeat measure 
linear regression between SEPP1 and birthweight. Adjusted estimates included age, smoking, alcohol consumption, BMI, ethnicity, UIC and vitamin 





4.1 Selenium, Glutathione Peroxidase 3 and Selenoprotein P 
Selenium adequacy at population level is based on the concentration required to 
maximise GPx3 output. This threshold is currently set at 90-100 µg/L as proposed by 
Duffield et al. (1999) and Thomson et al. (1977) whilst assessing New Zealand 
selenium status in the general population. As per this guidance, the population of 
women assessed in this study cohort were found to have selenium levels 
considerably lower than these proposed optimal concentrations (see Table 18). 
Serum selenium status in this study was similar to a Spanish study which also 
quantified selenium status across all three trimesters of pregnancy (Navarro et al., 
1996). Mean concentrations in the Spanish study indicated that selenium was sub-
optimal throughout gestation, however it remained fairly consistent across the 
trimesters (64.6, 66.6, 61.6 µg/L respectively). Furthermore, a Polish study also 
showed that selenium status fell linearly as gestation progressed, reaching its lowest 
concentration just before birth (35.7 µg/L between 35-40 weeks gestation) (Zachara 
et al., 1993).  
The selenium inadequacy seen in this study could be due to a number of factors. 
Firstly, pregnant women may not be obtaining the required dietary selenium intake to 
support both maternal demands and placental transfer of selenium to the foetus for 
growth and development (Mistry et al., 2014; Zimmermann and Kohrle, 2002). 
European soils, including the UKs, are known to be lower in selenium concentration 
compared to other continents such as the Americas. This in turn can give rise to 
dietary selenium insufficiency. Selenium enters the food chain through plant amino 
acid metabolism, therefore low soil concentration means less selenium uptake by 
mammals and a reduced amount of the micronutrient in certain foods (Schomburg 
and Kohrle, 2008). This low selenium intake aligns with the latest NDNS survey 
where 47% of women at child bearing age were below the lower reference nutrient 
intake for selenium (there are no measurements for women during pregnancy) 
(Public Health England, 2018). Trading regulations can also have an impact on 
selenium status of a population. For example, the reduction of flour imports from the 
USA after the UK joined the EU saw the UK turn to local flour varieties. The 
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implication of this was a sharp fall of selenium content in bread and inherently, the 
general population (Rayman, 1997).  
The decreasing levels of serum selenium throughout gestation could also be the 
result of plasma volume expansion (PVE). During pregnancy, PVE is necessary to 
facilitate the increased circulatory needs of the placenta and maternal organs. With 
on average, an increase by ~45% throughout gestation, PVE could be diluting serum 
selenium concentration, leading to these low levels (Faupel-Badger et al., 2007).  
As expected, the correlations shown in Figure 17 and the results of the regression 
analysis show that selenium is a significant predictor of GPx3 expression throughout 
the course of pregnancy. Similar results have been shown in a study by Zachara et 
al. (1993) who found plasma selenium levels in pregnant Polish women correlated 
positively with plasma GPx activity. This adds to the body of research showing that 
increased selenium concentrations through adequate selenium intake results in 
increased GPx3 synthesis. Sec, the core selenium constituent of selenoproteins, is 
reliant upon sufficient selenium availability for optimal protein expression and is 
sensitive to decreased selenium intake (Duntas and Benvenga, 2015). Low levels of 
GPx3 throughout pregnancy could also indicate an increased need for anti-oxidative 
protection during growth and development. An increase in oxygen requirements for 
both mother and child subsequently increases production of ROS. This is due to an 
increase in metabolic rate and increased oxygen consumption (Soma-Pillay et al., 
2016) Owing to its antioxidant properties, high concentrations of GPx3 may be 
needed to ensure adequate protection (Pieczynska and Grajeta, 2015).  
This study unexpectedly showed that serum selenium had an inverse association 
with SEPP1 (as seen in Figure 18). This is in contrast with studies such as Santos et 
al. (2017) who found selenium was a positive predictor of SEPP1 status. With 10 
selenocysteine residues per SEPP1 molecule and the fact that SEPP1 is reflective 
of ~50% of plasma selenium (Papp et al., 2007), it was anticipated that the higher 
levels of selenium needed for selenocysteine generation would result in higher levels 
of SEPP1, however the results of this study did not reflect this. The increase in 
median SEPP1 concentration throughout gestation was also unexpected. Whilst 
literature is lacking for trimester specific concentrations of SEPP1 and its potential  
consequences during pregnancy, Burk et al. (2013) found in mice models that SEPP1 
concentration decreased rather than increased through the later stages of gestation 
due to receptor mediated uptake of SEPP1 to the developing foetus. Therefore, within 
this study a potential explanation for the increase in SEPP1 could be that the low 
selenium environment witnessed in this cohort of women has prompted SEPP1 
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facilitation to compensate for this deficit. As the main transporter and distributor of 
selenium, the increased demands during pregnancy could be causing selenium 
homeostasis imbalance (Ventura et al., 2017).  
It is also been shown that foetal stores of selenium accumulate in the liver, kidneys 
and heart towards the end of the third trimester. A study in Poland showed the 
selenium concentrations in all three of these organs were higher in deceased full-
term infants compared to deceased premature foetuses (Zachara et al., 2001). It has 
therefore been suggested that this could be the result of an active transport system 
of selenium via SEPP1 across the placenta during the latter stages of pregnancy 
(Kasik and Rice, 1995).  
Selenoproteins are organised and expressed in a specific hierarchy in periods of 
limited selenium status (Schomburg and Schweizer, 2009). SEPP1 is relatively high 
in the hierarchy, making it one of the most stable selenoproteins under selenium 
deficient states. This allows the concentrations of this protein to remain conserved in 
critical organs such as the brain and thyroid (Solovyev et al., 2018; Hill et al., 2003). 
In comparison, GPx3 is much lower in the hierarchical system, resulting in falling 
concentrations of this protein in a selenium deficient state (Brigelius-Flohe and 
Maiorino, 2013; Mostert, 2000). The results seen from this study looks to support this 
theory. SEPP1 concentration appears not to be affected, increasing throughout 
pregnancy whereas GPx3 is more sensitive to selenium status, resulting in 
decreased concentrations as serum selenium falls throughout gestation. This is likely 
to be the result of premature termination of GPx3 protein synthesis or a decreased 
concentration of GPx3 mRNA expression (Wingler et al., 1999). 
It is apparent from this study that the selenium concentration in this UK cohort of 
women is not sufficient to sustain GPx3 concentration. At present, there is no UK 
specific guidance for pregnant women regarding the levels of selenium required to 
sustain a healthy pregnancy. Given that selenium is an essential micronutrient for 
selenoprotein expression and thyroid hormone activation in foetal development 
(Chan et al., 2003), research is urgently required to provide reliable estimates that 
will optimise selenium and selenoproteins during this critical time. In addition, the 
most appropriate biomarker to determine selenium adequacy is not well established 
i.e. SACN guidelines refers to the concentration of selenium required for maximal 
GPx expression whereas the European Food Safety Authority use maximal SEPP1 
expression in order to derive dietary intakes (EFSA Panel on Dietetic Products and 
Allergies, 2014; SACN, 2013). This inconsistency warrants further study to establish 
universal definitions on how to assess selenium status. Whilst dietary intake of 
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selenium will vary by country as geochemical conditions change, it is only reasonable 
that the same biomarker should be used in comparisons for consistency. This will 
facilitate a greater understanding within the field.  
4.2 Iodine and Thyroid Hormones 
A median urinary iodine concentration of 150-249 µg/L defines iodine sufficiency 
during pregnancy as per the WHO guidelines. Where concentrations fall below the 
150 µg/L threshold, pregnant populations would be deemed as iodine insufficient, 
indicative of suboptimal iodine intake (World Health Organisation, 2007). As per 
these limits, the cohort of women within this study would be classified as iodine 
deficient across the entire duration of pregnancy (103.4, 120.8 and 112.1 µg/L 
respectively). Results found here reflect the current body of existing research. A UK 
based longitudinal study performed by Furmidge-Owen et al. (2014) witnessed 
extremely low iodine levels across all three trimesters of pregnancy (42, 52 and 69.4 
µg/L respectively). A Spanish study also found suboptimal iodine levels throughout 
the first two trimesters of pregnancy. 79.8% (median UIC: 88.5 µg/L) and 54.4% 
(median UIC: 40 µg/L) of women at trimesters one and two respectively, had an UIC 
lower than the 150 µg/L adequacy limit (Aguayo et al., 2013). Bath et al. (2014) found 
that the median urinary iodine concentration (UIC) in a population of 100 women in 
the South East of England during the first trimester was 85.3 µg/L and Snart et al. 
(2019) found women across three locations in the UK (Leeds, London and 
Manchester) were iodine insufficient in the second trimester of pregnancy (median 
UIC levels 116, 130 and 139 µg/L for each location respectively). However, a 
Bangladeshi study by Rydbeck et al. (2013) found that median UIC concentrations 
from a population of 271 pregnant women rose throughout gestation and had 
adequate UIC (241, 268, 296 and 300 µg/L at 8, 14, 19 and 30 weeks respectively). 
In a geographical location known for optimal iodine intakes within the general 
population, it is no surprise to see adequate UIC levels in the Bangladeshi cohort of 
women. This will most likely be the result of a mandatory USI programme 
implemented within this area, providing adequate iodine intake on a population level 
(Yusuf et al., 2008). However, the results obtained from the Spanish and UK studies 
represents the ongoing iodine insufficiency experienced throughout the majority of 
Europe (Zimmermann and Boelaert, 2015). Geochemistry, combined with a lack of 
mandatory USI programmes in these European areas gives rise to insufficient iodine 
intake resulting in low UIC status (Zimmermann, 2009b). The lowest UIC in the 
current study was reported at the first visit (103.4 µg/L). During this early period of 
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gestation, thyroid hormone receptors present in the foetal brain ensure normal foetal 
myelination via maternal T4 placental transfer (Gernand et al., 2016). Low UIC status 
witnessed in this study could therefore be increasing the risk of IDD’s such as 
neurological cretinism due to an increased risk of potential impairment of sufficient 
thyroid hormone metabolism (Zimmermann, 2011).  
Basic ethnicity analysis showed a significant increase in mean iodine concentration 
for Pakistani women compared to those of White-British ethnicity (Table 17). The 
results from an Australian study by Hamrosi et al. (2005) mirrored this study’s 
findings; pregnant Caucasian groups had a lower overall UIC concentration 
compared to Vietnamese and Indian/Sri Lankan women. There is known to be a 
number of differing predispositions within ethnic groups such as potential genetic 
variabilities, socioeconomic status, dietary intake and general cultural differences, all 
of which could have had an impact on UIC status. Further exploratory subgroup 
analysis with a larger sample size would be beneficial as the small numbers in each 
group (as seen within this study) leads to difficulty interpreting results due to the low 
statistical power.  
There were no major fluctuations in thyroid hormone concentrations across 
pregnancy (Table 18). A Dutch study showed a very similar trend for serum TSH and 
fT4 levels in comparison with our project. With consistent small increases in TSH 
(1.23-1.51µIU/mL) and small decreases in fT4 (12.4-10.3pg/mL), results were 
indicative of a population with normal thyroid function throughout the entirety of 
pregnancy (Monen et al., 2015). During normal pregnancy, fT3, fT4 and TSH 
concentrations can be attributed to the stimulatory effect of the pregnancy hormone 
hCG. A fall in TSH concentration of up to 50% and a rise in fT3 and fT4 have been 
witnessed, peaking during the first trimester at around 10-12 weeks gestation. As 
gestation progresses, TSH starts to rise and fT3/fT4 decreases, however the precise 
reasons for this is still unclear (Lazarus, 2011). Reference limits have also been 
recommended for TSH and fT4 in the absence of laboratory specific reference 
ranges. According to guidelines set by the European Thyroid Association and The 
Endocrine Society, TSH values are within a normal range if concentrations are below 
2.5µIU/mL in trimester 1 and 3µIU/mL in trimesters 2 and 3 (Lazarus et al., 2014; De 
Groot et al., 2012). The American Thyroid Association have recently updated their 
guidelines to reflect that the upper limit should not surpass 4µIU/mL (Alexander et 
al., 2017). Whilst we have no baseline data to compare the drop in TSH levels from 
pre-pregnancy to first trimester, if we were to apply the results to the criteria provided, 
women in this cohort appear to have normal thyroid hormone concentrations which 
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is indicative of a normal pregnancy and a subsequent low risk of developing 
subclinical or overt hypothyroidism.  
Reference ranges for thyroid hormone function tests differ throughout gestation 
compared to the non-pregnant population (Lazarus, 2011). Profound physiological 
changes in the thyroid as a result of increased demands from the foetus causes 
increases in thyroid hormones to meet maternal and foetal requirements (Stricker et 
al., 2007). Therefore, it is imperative that trimester specific reference ranges during 
pregnancy must be used during this period. At present, pregnancy criteria for thyroid 
hormone concentrations tends to be centre specific between countries/populations; 
there is no global guidance on reference ranges due to a number of influencing 
factors such as iodine status, ethnicity, BMI, age and laboratory methodologies used 
(Moon et al., 2015; Medici et al., 2015). This is understandable when studies such as 
Li et al. (2014) demonstrate the pitfalls of using of global TSH criteria during 
pregnancy. 4800 Chinese women had TSH assessed against both centre specific 
criteria (upper limit TSH>4.87mIU/L) and the American Thyroid Association criteria 
(upper limit TSH>2.5mIU/L at time of analysis). It was found that during 4-12 weeks 
gestation, 27.8% of the women would be classed as at risk of subclinical 
hyperthyroidism by American Thyroid Association criteria compared to just 4% of 
women when using centre specific reference ranges. This proves the variation and 
influencing factors between countries. However, the current WHO UIC criteria for 
pregnancy is a globally accepted measure of iodine status irrespective of the current 
iodine status of a country, ethnicity/BMI of the population and the laboratory 
methodologies used. When the influencing factors are the same for UIC reference 
ranges, it could be asked why there are no globally accepted gestational thyroid 
hormone limits? It could be beneficial to implement a standardised laboratory 
methodology for the determination of thyroid hormone reference ranges to eliminate 
one of these factors of variability. For example, there is controversy surrounding 
which method is suitable for this quantification. Some literature states that 
immunoassay is a sufficient measure whereas others claim LC/MS is the ‘gold 
standard’ (Lazarus et al., 2014). The WHO EQUIP programme has aimed to 
standardise UIC determination. A similar approach could well be needed to define 





It would have been presumed that iodine and associated thyroid hormones would be 
associated in some capacity due to iodine being a direct regulator of thyroid hormone 
expression. However, this study did not find evidence for this. There were weak/no 
associations between fT3, fT4 and TSH with UIC throughout pregnancy (Table 18). 
A number of studies have found similar results. A Spanish study by Aguayo et al. 
(2013) and a French study by Luton et al. (2011) found little evidence of any 
associations between UIC and these corresponding thyroid hormones. The results 
from this study could be due to UIC analysis not being a good enough measure of 
iodine status within this small cohort. Hydration levels affect smaller sample sizes 
more profoundly in comparison to studies with larger sample sizes, leading to 
common misinterpretations (Zimmermann, 2009a). Also, iodine stores may have 
been sufficient prior to pregnancy. It is thought that adequate iodine concentrations 
before gestation are able to maintain both maternal and foetal hormone requirements 
(Yarrington and Pearce, 2011). However, without baseline data, this is hard to 
deduce. Although there are no associations between UIC and fT3, fT4 and TSH, 
there is a suggestion that thyroglobulin and UIC may be inversely associated, though 
this observation did not reach statistical significance (p=0.06). Whilst the result did 
not display a significant result, the overall trend shown agrees with Bath et al. (2017) 
who also found an inverse association of thyroglobulin with UIC in the UK based 
SPRINT cohort. Thyroglobulin is thought to be a very sensitive marker of iodine 
deficiency – a raised concentration is indicative of thyroid enlargement and stress 
resulting in the release of this protein into the blood circulation (Ma and Skeaff, 2014). 
The results from this study reflect this observation as thyroglobulin concentrations 
tends to be higher in individuals with a lower UIC status.  
This study design relied on spot urine collection to measure UIC. As briefly 
mentioned, spot urines are more effective with bigger sample sizes as variable 
hydration levels between individuals are levelled out within larger populations 
(Zimmermann, 2009). For this study, the low sample size (70 participants) means 
that spot UIC levels may be influenced by a number of factors including hydration 
levels and the diurnal variation of iodine (Alexander et al., 2017). This can lead to 
common UIC misinterpretations. To overcome these limitations, the use of 24-hour 
urine samples would have been the preferred method of collection (Zimmermann, 
2009), however, the impracticalities of doing so meant that spot urine analysis was 




4.3 Selenium, Iodine and Thyroidal Interactions  
Sufficient selenium and iodine intakes are imperative for normal thyroid hormone 
synthesis and metabolism (Zimmermann and Kohrle, 2002). This is the only UK 
based cohort study that has assessed both selenium intake and its potential impact 
on iodine and thyroid hormones throughout gestation. Results from the regression 
analysis after adjustments for confounding showed that there were no significant 
associations between selenium and iodine (p=0.40), selenium and fT4 (p=0.20), 
selenium and fT3 (p=0.34), selenium and TSH (p=0.50) and selenium and 
thyroglobulin (p=0.31). Due to a lack of research investigating these associations 
throughout pregnancy, comparisons have been undertaken in non-pregnant 
populations. Our findings reflect the results found in two New Zealand studies. 
Thomson et al. (2007a) found no correlation or association with selenium and thyroid 
status (fT4, fT3 and TSH) in both male and female adults, however, positive 
correlations were witnessed between urinary selenium and urinary iodine (p<0.001). 
In the second study, Thomson et al. (2009) found that in 100 subjects aged 60-80 
year olds, there was no interactions between mild iodine deficiency and low selenium 
status.   
The small non-significant positive correlation between serum selenium and urinary 
iodine at all visits (Figure 24) could potentially be attributed to dietary and 
supplementary intake. Some food items such as fish are rich sources of both 
selenium and iodine. In addition, for those women taking supplements containing 
both selenium and iodine, results would be expected to be slightly correlated as 
women would be consuming the required dietary intake of both micronutrients. In 
contrast, the lack of a significant association could be due to the specimen collection 
methods. Firstly, differences in matrices could have an effect on results (serum 
selenium vs urinary iodine). Spot urines collected for the project are very susceptible 
to large amounts of variation due to reasons as described in section 4.2. This could 
have had an influential effect when calculating accurate iodine measurements. In 
addition, selenium and iodine are utilised in completely different metabolic pathways. 
The only known biological role for iodine is T3 and T4 synthesis (Arthur et al., 1999) 
and selenoprotein production only requires selenium specifically for Sec production 
(Papp et al., 2007). There is no further requirement for either of these trace elements 
other than for their respective protein pathways i.e. T3 and T4 do not require selenium 




As the key mediator in thyroid hormone metabolism, DIO require sufficient selenium 
for Sec production. This amino acid is key for normal DIO1 and DIO2 functionality, 
catalysing the 5’ outer ring to produce T3 from T4 (Labunskyy et al., 2014). In periods 
of selenium deficiency as seen in this study, it would have been expected to 
potentially see an inverse association with selenium and T4 due to potential 
impairment of DIO expression (lack of DIO, reduced conversion of T4 to T3, higher 
T4 concentrations). As defined by Thomson (2004), optimal deiodinase expression 
occurs when serum selenium concentrations reach ~65 µg/L. This threshold was met 
during the first visit only; serum selenium falls short of this limit during the latter two 
time points. However, overall the results seem to suggest serum selenium was 
sufficient for DIO expression throughout gestation. Firstly, TSH and T4 
concentrations remained within their expected normal limits throughout pregnancy. If 
there was any deiodinase impairment, we may have seen a sharp rise in 
concentration of both of these thyroid hormones. The T3/T4 ratio assessment can be 
implied as a good indicator of DIO activity (Zimmermann and Kohrle, 2002). As seen 
in Table 21, the consistent fT3/fT4 ratios for all visits across pregnancy indicates 
consistent conversion from fT4 to the active thyroid hormone fT3, hence normal DIO 
activity (Olivieri et al., 1996; Thomson et al., 2009). Thirdly, as selenium 
concentration is at its lowest within the last trimester, there is no association between 
selenium and fT4 at this time point – an inverse association would have been 
expected should there had been a decline in DIO expression. Lastly, it may be the 
case that the 65 µg/L threshold set by Thomson (2004) may not be absolute. The 
selenoprotein hierarchy ranks the DIO family of selenoproteins highly. This means in 
periods of limiting selenium supply, these selenoproteins are continually expressed 
(Bermano et al., 1995). In this study, it could be the case that the selenium 
concentration is sufficient for DIO expression and is prioritised over other 
selenoproteins such as the more selenium sensitive GPx3 (as seen by the falling 
median concentration of GPx3 as gestation progresses) to ensure that thyroid 
hormone metabolism is maintained.  
It would have been hugely beneficial to measure the concentration of maternal DIO 
(DIO1, DIO2 and DIO3) in this study due to their pivotal role in thyroid hormone 
metabolism. This would have enabled us to investigate how DIO concentrations 
change (if at all) throughout pregnancy and to determine if lowering selenium 
concentration had any impact on the DIO expression. This analysis would be a key 




As participants in this study were only mildly iodine deficient and selenium 
insufficient, further research and studies are warranted to establish if and how mild 
deficiencies have the potential to effect the thyroid axis. It is well known that in periods 
of selenium deficiency, thyroidal selenium and selenoprotein regulation tends to be 
unaffected due to the selenoprotein hierarchical system (Bermano et al., 1995). It is 
therefore more likely that interactions between the two micronutrients may only have 
a profound effect when exhibiting severe deficiencies in iodine and selenium i.e. as 
seen in the manifestation of myxoedematous cretinism.  
4.4 Selenium and Dietary Intake 
This is the first UK study to assess dietary selenium intake and its impact on selenium 
concentration throughout gestation. Results from correlation and regression analyses 
found that dietary selenium assessment was not a significant predictor of serum 
selenium status. Previous research investigating this association has been 
conflicting. A study by Thomson et al. (2007b) found that in 5-14 year old children, 
dietary selenium was positively associated with plasma selenium levels (p=0.006) 
after multiple regression, however a study performed by Lane et al. (1983) in female 
elderly subjects (age range: 65-92 years) found that there was no correlation between 
plasma selenium and dietary selenium intake (rp=0.13).  
The myfood24 tool used in this study is a comprehensive 24-hour dietary recall 
assessment, making it a more substantiated method to collect dietary information 
compared to food frequency questionnaires (FFQ). The variety of food options 
available on the myfood24 programme allows diverse groups with varied food intakes 
to use the tool accurately, building recipes using specific ingredients when required. 
The minimal burden placed on users also means it is easy to conduct and simple to 
understand (Wark et al., 2018). However, whilst dietary recalls are one of the most 
feasible methods of collecting dietary data, they are still prone to issues. Participants 
may inaccurately recall food items as this method relies on memory. In addition, users 
may subjectively report food items and portion sizes, introducing the risk of recall bias 
(Shim et al., 2014). This could lead to inaccurate dietary selenium calculations.  
Food importation and the bioavailability of selenium within foods also has the ability 
to drastically affect accurate assessments of dietary selenium status. The selenium 
content of food imported from different geographical areas can vary in selenium 
concentration due to properties of the soil effected by factors such as pH, rainfall and 
rock type (discussed in sections 1.1.2 and 1.1.3). This means that country specific 
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nutritional food tables tend to be inaccurate (Stoffaneller and Morse, 2015). As a 
result, it may be that the default selenium intake values calculated within the 
myfood24 tool may not be representative of the true selenium intake. Food 
composition also has an influence on the selenium bioavailability. For example, whilst 
fish produce is known to be a good source of selenium, it also contains high levels of 
heavy metals such as mercury and arsenic. Interactions between these elements 
result in strong inorganic complexes between selenium and these elements, making 
selenium unable to solubilise in the body. This results in a decrease in bio-
accessibility needed for further metabolic processes after absorption (Thiry et al., 
2012; Navarro-Alarcon and Cabrera-Vique, 2008). Whilst myfood24 may report a 
selenium value from known food tables, the concentrations in the blood may not 
reflect this as the selenium is unable to be utilised. Selenium from potential 
supplementation use was also not calculated in the dietary estimates. With the 
majority of women taking supplements in this study, dietary intake may have been 
underestimated resulting in inaccurate calculations of selenium intake. A combination 
of these drawbacks may well have been a factor in the lack of correlation seen 
between dietary selenium assessment and biomarker status as seen in this study  
Dietary data taken in this study is a short term assessment of dietary intake over 
three, 24 hour periods during pregnancy. Whilst the three visits aim to give a good 
representation of normal dietary consumption, it would have been beneficial to gather 
dietary data for a longer duration of time to assess longer-term selenium intake. For 
example, the day-to-day variation in dietary intake of certain selenium containing 
foods i.e. nuts and fish may not be captured in a 24-hour recall if eaten a few days 
earlier (Thomson et al., 2007b). Instead of using serum selenium which is a short 
term indicator, whole-blood, hair and toenail samples are thought to give a better 
longer-term evaluation of selenium concentration (Rayman et al., 2015). Assessing 
one of these matrices with longer term dietary data may have been more beneficial 
approach to examining an association between dietary selenium and body selenium 
status as changes in selenium status are more apparent long-term. As well as 
measuring serum selenium, it would be useful in future work to identify whether GPx3 
and SEPP1 correlate with dietary selenium. These key biomarkers are thought to 
give a better indication of selenium status, reflecting the amount of selenium required 
for normal selenoprotein synthesis (Thomson, 2004). It would have also been 
advantageous to know the specific food groups consumed by this cohort of women 
using the myfood24 tool i.e. fish, meats, vegetables. Food sources have varying 
selenium bioavailability due to a wide range of factors i.e. the speciation of selenium 
contained in the food (organic or inorganic selenium – section 1.1.4). Organic 
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selenium tends to be more bioavailable, has a greater retention and accumulates 
more readily in organs and tissues compared in inorganic selenium sources (Thiry et 
al., 2012). By deducing which foods were eaten, it may indicate which type of 
selenium speciation was probably absorbed, thus reflecting in the serum selenium 
levels. For example, meat has higher levels of bioavailable SeMet and Sec meaning 
we would anticipate higher serum selenium/biomarker concentrations.   
4.5 Selenium and Birthweight  
Whilst the assessment of selenium and pregnancy related complications such as 
preeclampsia and pre-term birth have been explored in the UK (Rayman et al., 2003; 
Rayman et al., 2014; Rayman et al., 2011), the effect of selenium concentration on 
birthweight had yet to be studied. Investigating for the first time in a UK based 
population, it was found that in early gestation (visit one), serum selenium levels were 
a significant predictor of birthweight (adjusted regression β=15 g, 95% CI 2 to 30 g, 
p=0.02). This was in contrast to the latter two visits where no such associations were 
found. The associations between selenium and birth weight in the prior literature give 
conflicting results. Bogden et al. (2006) found that USA mothers with selenium 
concentrations in the lowest decile during the early stages of pregnancy, predicted 
low birth weight in full term infants. Similar results were also found in a Japanese 
study. Tsuzuki et al. (2013) found that maternal selenium concentration at the third 
trimester was positively associated with birthweight (p=0.015). However, a study in 
Polish women also assessed selenium status of the mother and the resulting 
birthweight of the neonate at point of delivery (third trimester). It was found that 
maternal selenium levels at this point had no association with low birth weight 
(Wasowicz et al., 1993). A case controlled study in Iran found similar results; 
selenium and low birth weight were not significantly associated (Mohammadzadeh et 
al., 2009).  
It is well established that thyroid hormones are important in foetal development as 
seen by the presence of thyroid hormone receptors and selenium containing DIO in 
early gestation within the foetal brain (Chan et al., 2002). A study conducted by Chan 
et al. (2003) found that mRNA expression of DIO2 and DIO3 was significantly 
elevated throughout the first trimester compared to the latter two trimesters, signifying 
the importance of DIO during early gestation. Whilst it has been deduced that DIO 
expression is probably sufficient in this cohort of women for optimal thyroid hormone 
supply in part due to the selenoprotein hierarchical system, it is still deficient for 
optimal expression of other important selenoproteins such as GPx3 and SEPP1. The 
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association between GPx3 and birthweight gave similar conclusions as seen for 
serum selenium (see Table 25). During the first visit, GPx3 was significantly 
associated with birthweight (unadjusted, p=0.019), whereas results from the second 
and third visits found no associations. As described earlier, sufficient selenium levels 
are required for optimal GPx3 expression. In this study, it was found that selenium 
was inadequate for GPx3 expression, resulting in lower GPx3 concentration giving 
the potential for weakened antioxidative defence mechanisms (Mistry et al., 2008). 
The reduction in GPx3 concentrations early in pregnancy could affect foetal growth 
due to the overexposure of ROS, causing extensive DNA and lipid damage during 
the most sensitive trimester (Mistry et al., 2012). After this point, the increased 
transportation of SEPP1 across the placenta (specifically in the last trimester) could 
increase the stores of selenium which the foetus is known to accumulate in its vital 
organs (Zachara et al., 2001). This increase may indicate why there was no such 
associations during visits two and three. 
The reasons why we have seen a significant association between selenium and its 
biomarkers at the first visit only is not inherently clear. With conflicting results from 
previous studies (as mentioned), further research is required to fully determine the 
effects of low selenium during pregnancy and its influence on birth weight. This will 
enable us to discover, understand fully and confirm the mechanisms of selenoprotein 
expression and function during early gestation and whether it has a significant impact 
on foetal clinical outcome.  
4.6 Strengths and Limitations 
This study has its strengths and limitations. One of the biggest strengths lies within 
its design. Women agreed to partake in detailed data collection periods where 
anthropometric assessments, blood/urine samples, questionnaires and food diaries 
were all taken. Assessments for each woman in this small cohort was successfully 
collected across the three visits spanning gestation (i.e. 3x blood samples, 3x urine 
samples, 3x questionnaires and 3x 24-hour dietary recalls were all collected). This 
meant we had the ability to attain a true reflection of changes across the course of 
pregnancy– a feat which improves upon the methodology of other studies such as 
Knight et al. (2017) and Santos et al. (2017) who only had the ability to assess iodine 
concentrations during the third trimester and selenium concentrations at time of birth, 
respectively. This has allowed us to investigate a wealth of novel questions in this 
study. For example, no prior UK study has investigated associations between 
selenium and birthweight throughout the entirety of pregnancy, nor has one 
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examined correlations between dietary selenium and serum selenium status. All 
future work using this data will have the ability to investigate other important, 
contemporary questions.  
Seventy participants were successfully retained throughout the project. This is a key 
strength, however it has been potentially limiting. This study has similar participant 
numbers to other studies, such as Mistry et al. (2008) and Bath et al. (2014) who 
analysed data from 74 and 100 participants, respectively. With the strong design 
allowing multiple time points across pregnancy and the sheer amount of high quality 
information collected at each visit, to have 70 participant complete the study with a 
full set of data reflects a very successful recruitment and retention process. However, 
despite having a large quantity of data, the participant number is relatively small and 
does increase the risk of unwanted variability and bias which has resulted in the study 
having less statistical power than originally hoped.  
The cohort of pregnant women in this study were recruited in the UK city of Bradford. 
As a highly diverse area, it has the ability to give a unique assessment of how differing 
factors such as ethnicity, socioeconomic status and environmental factors affects 
micronutrient status throughout pregnancy. Whilst this cohort and its large amount of 
diversity may not be truly representative of the British population unlike others such 
as the ‘Avon Longitudinal Study of Parents and Children (ALSPAC)’ cohort, ours is 
still generalizable, novel and could be classed as a measure of the changing 
population status as seen throughout certain areas of the UK within the past 20-30 
years.  
During recruitment, participants were informed on the project aims and what the 
effect iodine can have during pregnancy. In turn, the heightened awareness of how 
these micronutrients may impact foetal growth and development may have made 
them more aware of the importance of micronutrient intake during pregnancy. This 
may have resulted in an improved diet and additional supplementation usage. This 
has the potential to effect the usual selenium and iodine dietary intake values (as 
discussed in section 4.4), leading to an increased risk of bias. Further studies into 
the exact supplementation content taken across all pregnancy is warranted to 
determine whether high usage had an effect on both iodine and selenium 
concentration, i.e. many supplements listed could simply have been the 
recommended folic acid. To have potentially eliminated this risk, a more blinded study 
design may have been beneficial. Baseline controls from non-pregnant women were 
also not collected, which may have improved the generalisability of this study. In the 
absence of this data, it makes it difficult to conclude whether there was a true 
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modification in concentrations and relationships in comparison to a non-pregnant 
population. There would be no justifiable basis to potentially recommend any 
changes in public health guidance without this information. 
The ICP-MS analyses conducted for this study were of the highest accuracy and 
precision. The University of Leeds participated in the CDC EQUIP global programme 
which aims to standardise laboratory urinary iodine quantification. During 
participation, our laboratory centre passed all global criterion, equalling 
concentrations of iodine sent by the programme using our own ICP-MS 
instrumentation. This ensured that all iodine results were of the highest possible 
accuracy. In regards to serum selenium quantification by ICP-MS, the use of two 
external quality controls alongside a validated CDC methodology ensured high 
accuracy throughout. Seronorm™ Trace Elements and UK NEQAS samples were 
ran in each run with results comparing extremely well to expected values. This has 
ensured the data obtained is as reliable possible. However, there were also some 
laboratory limitations within this study. During ICP-MS development for serum 
selenium, the most abundant selenium isotope (Se80) was not quantified alongside 
Se77 and Se78. This was the result of interference from Ar40Ar40 dimers within the ICP-
MS plasma torch, raising the potential for inaccurate measurements by mistakenly 
detecting dimers as Se80. Whilst the exclusion of quantifying Se80 did not raise any 
issues during serum selenium analysis (all external and internal QC samples were 
accurate as per Certificates of Analysis), it may have been beneficial to optimise the 
instrumentation for longer to potentially avoid excluding this Se80 isotope or use a 
different method of quantification in order to include this isotope. However, financial 
and time constraints meant that this was not possible.  
No validatory quality controls were used in SEPP1 and GPx3 ELISA analysis due to 
time constrains and funding. Whilst kits were pre-validated from the manufacturer 
and samples were run in duplicate with strict criteria on acceptance, no incurred 
sample repeat analysis or inter-run precision was performed. A basic test to monitor 
the level of anti-thyroglobulin and anti-TPO antibodies before thyroid hormone 
analysis was also not conducted in these maternal samples. Anti-thyroglobulin 
antibodies are widely known to influence thyroid hormone concentrations, increasing 
the likelihood of inaccurate results (Bath et al., 2017). With no measurements taken 
in this study due to time, funding and laboratory practicalities, biomarker results must 
be analysed with caution.  
94 
 
4.7 Future Work 
A key piece of future work would be to use a larger sample size to increase statistical 
power. This project has shown some interesting, novel results especially in regards 
to assessing selenium throughout the course of pregnancy and the effects of the 
micronutrient on birth weight within the UK. It would therefore be a priority to repeat 
this analysis with an increased power to determine more conclusively the impact 
these results could have on pregnant women.  
Basic comparisons between the two main ethnic groups of participants (Pakistani 
and White-British) and their biomarker status was briefly analysed during this study, 
however it would be beneficial to perform further complex analysis with higher sample 
numbers to determine whether there is a substantiated difference between the two 
groups. For example, the cultural differences and its impact on dietary intake may 
demonstrate some important results. The south-east Asian diet tends to be unlike 
that of a western diet. Using the myfood24 data, it would be interesting to see firstly 
how micronutrient status differs between the two groups and secondly, whether 
particular foods gives rise to lower or higher selenium and iodine status in these 
populations. In addition, it would be beneficial to compare concentrations of 
selenium, iodine and their respective biomarkers of those individuals that have taken 
iodine and selenium containing supplements throughout pregnancy compared to 
those that have not. This would enable us to discover whether supplementation had 
a positive effect in raising concentrations. Myfood24recalls would also be able to 
distinguish in those that did not take supplementation, which foods were of greater 
effect in providing the necessary micronutrients.  
Future work would also benefit from the refinement of existing laboratory methods 
alongside the use of additional techniques to help consolidate results. For example, 
further method development using the ICP-MS instrumentation may rectify the argon 
dimer interference as seen with the selenium isotope, Se80. The increased sensitivity 
and low detection limits of a triple quadrupole ICP-MS has the ability to quantify Se80 
if utilised correctly. With more time going forward, serum selenium precision and 
accuracy could be improved. In addition, the use of different quantification methods 
i.e. western blotting alongside ELISA analysis would confirm the precision and 





This study has raised important issues regarding the nutritional status of pregnant 
women within the UK. Being one of few pieces of work to assess a multitude of 
biomarkers over the course of gestation, it is apparent that women in this cohort are 
both iodine and selenium insufficient according to the relevant guidelines (World 
Health Organisation, 2007; Thomson et al., 1977). This is consistent with other pieces 
research that continue to highlight concerning micronutrient deficiencies within 
pregnant populations. We have also shown for the first time in the UK that selenium 
may impact early gestation during critical periods of growth and development. With 
the results showing just a 10 µg/L increase in serum selenium concentration leading 
to as much as a 150 g increase in birthweight during the most important trimester of 
pregnancy, the clinical implications of this discovery could be of very high 
significance. Further research is warranted to consolidate these findings within a 
larger sample size however, in the short term it is apparent is that public health 
education and recommendations regarding the importance of optimal nutrition 
throughout pregnancy must be communicated more efficiently to mothers. 
Heightened awareness of the increased risks a poor diet can have on the developing 






5.1 Appendix 1: HIBA Questionnaire Examples 
__________________________________________________________________ 
SECTION A  PARTICIPANT INFORMATION 
1. Date completing questionnaire  /  /      
Day        Month   Year 
 
2. Who is administering the questionnaire? ______________________________ 
3. Language used for administration  English 
      Punjabi 
      Urdu 
      Other: ____________ 
 
4. Interpreter used 
 Yes   No   
If yes, who is the interpreter? 
      Family or friend 
      Other 







6. Who is taking the measurements? ________________________________ 
       
7. Height      .  cms   
  Not able to take 
8. Current Weight     .  kgs   
  Not able to take 
9. Resting pulse rate     bpm    
  Not able to take 
 __________________________________________________________________ 
SECTION B BACKGROUND  
 
This first section is about your background.  
20. What is your date of birth?   
 
 /  /      
Day        Month      Year 
 
21. What country were you born in? 
 
 England     Northern Ireland   Poland 
 Pakistan     Scotland    Czech Republic 
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 Bangladesh     Wales    Slovakia 
 India     Republic of Ireland   Romania  
 Hungary  
 Other: ________________________   
 
22. What country were your parents born in? 
 
Your mother:  Your father: 
 
     England      
  
     Pakistan     
     Bangladesh 
     India      
     Northern Ireland     
    
     Scotland 
     Wales 
     Republic of Ireland  
     Slovakia 
     Czech Republic 
     Poland 
     Romania 
     Hungary 
     Other:   
__________________________________________________ 
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